BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896. [PMID: 11910340 DOI: 10.1053/gast.2002.32418] [Cited by in Crossref: 871] [Cited by in F6Publishing: 766] [Article Influence: 43.6] [Reference Citation Analysis]
Number Citing Articles
1 Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver transplantation. Drugs 2007;67:871-85. [PMID: 17428105 DOI: 10.2165/00003495-200767060-00004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
2 Alzubiedi S, Saleh MI. Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection. American Journal of Therapeutics 2017;24:e670-5. [DOI: 10.1097/mjt.0000000000000356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Habrecht O, Settmacher U. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation. 2008;86:469-473. [PMID: 18698252 DOI: 10.1097/tp.0b013e31817c0e20] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl. 2009;15:1872-1881. [PMID: 19938138 DOI: 10.1002/lt.21954] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
5 Akamatsu N, Sugawara Y. Living-donor liver transplantation and hepatitis C. HPB Surg 2013;2013:985972. [PMID: 23401640 DOI: 10.1155/2013/985972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010;16:1228-35. [DOI: 10.1002/lt.22175] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 9.0] [Reference Citation Analysis]
7 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
8 Roche B, Samuel D. Aspects of hepatitis C virus infection relating to liver transplantation: . European Journal of Gastroenterology & Hepatology 2006;18:313-20. [DOI: 10.1097/00042737-200604000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
9 Van ND, Falk CS, Sandmann L, Vondran FW, Helfritz F, Wedemeyer H, Manns MP, Ciesek S, von Hahn T. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. Gut 2016;65:1015-23. [PMID: 25800783 DOI: 10.1136/gutjnl-2014-308003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
10 Chan SC, Fan ST, Lo CM, Liu CL, Wei WI, Chik BH, Wong J. A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg. 2008;248:411-419. [PMID: 18791361 DOI: 10.1097/sla.0b013e31818584e6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.5] [Reference Citation Analysis]
11 Londoño MC, Crespo G, Forns X. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013;18:271-8. [PMID: 23665543 DOI: 10.1097/MOT.0b013e3283614aca] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Ueda Y, Kaido T, Ito T, Ogawa K, Yoshizawa A, Fujimoto Y, Mori A, Miyagawa-Hayashino A, Haga H, Marusawa H, Chiba T, Uemoto S. Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation. Transplantation 2014;97:344-50. [PMID: 24157473 DOI: 10.1097/01.TP.0000435702.61642.0a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, Nakamoto N, Hibi T, Yagi H, Abe Y, Matsubara K, Chu PS, Wakayama Y, Taniki N, Yamaguchi A, Amemiya R, Miyake R, Mizota T, Kanai T, Kitagawa Y. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2016;46:1118-28. [PMID: 26854748 DOI: 10.1111/hepr.12666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Gelb B, Feng S. Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol 2009;3:631-47. [PMID: 19929584 DOI: 10.1586/egh.09.58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
15 Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, Schaubel DE. Liver and Intestine Transplantation in the United States, 1995-2004: Liver and Intestine Transplantation, 1995-2004. American Journal of Transplantation 2006;6:1170-87. [DOI: 10.1111/j.1600-6143.2006.01273.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
16 Roche B, Coilly A, Roque-Afonso AM, Samuel D. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses 2015;7:5155-68. [PMID: 26404355 DOI: 10.3390/v7092864] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
17 Tashiro H, Itamoto T, Ohdan H, Fudaba Y, Kohashi T, Amano H, Ishiyama K, Takahashi S, Aikata H, Chayama K, Arihiro K, Asahara T. Should splenectomy be performed for hepatitis C patients undergoing living-donor liver transplantation? J Gastroenterol Hepatol 2007;22:959-60. [DOI: 10.1111/j.1440-1746.2007.04951.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
18 Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat. 2016;23:408-418. [PMID: 27018088 DOI: 10.1111/jvh.12534] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
19 Ueda Y, Ikegami T, Soyama A, Akamatsu N, Shinoda M, Ishiyama K, Honda M, Marubashi S, Okajima H, Yoshizumi T, Eguchi S, Kokudo N, Kitagawa Y, Ohdan H, Inomata Y, Nagano H, Shirabe K, Uemoto S, Maehara Y. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience: Simeprevir-based triple therapy after LDLT. Hepatol Res 2016;46:1285-93. [DOI: 10.1111/hepr.12684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
20 Ravasio R. Costo efficacia di peginterferone α-2a + ribavirina versus peginterferone α-2b + ribavirina nel trattamento dell’epatite cronica di tipo C in pazienti HIV co-infetti. Pharmacoeconomics-Ital-Res-Articles 2008;10:37-47. [DOI: 10.1007/bf03320639] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 von Hahn T, Steinmann E, Ciesek S, Pietschmann T. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2010;4:63-79. [PMID: 20136590 DOI: 10.1586/egh.09.74] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
22 Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, Seo S, Machimoto T, Uemoto S. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142:685-694. [PMID: 17981188 DOI: 10.1016/j.surg.2007.05.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
23 Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010;CD006803. [PMID: 20091608 DOI: 10.1002/14651858.CD006803.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
24 Alem SA, Said M, Anwar I, Abdellatif Z, Elbaz T, Eletreby R, AbouElKhair M, El-Serafy M, Mogawer S, El-Amir M, El-Shazly M, Hosny A, Yosry A. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. J Med Virol 2018;90:1508-15. [PMID: 29718546 DOI: 10.1002/jmv.25210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Fenwick F, Bassendine MF, Agarwal K, Bevitt D, Pumeechockchai W, Burt AD, Toms GL. Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation. J Clin Pathol 2006;59:174-8. [PMID: 16443734 DOI: 10.1136/jcp.2005.028126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
26 Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban J, Esteban R. Removal from liver transplantation list of a hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir. Transpl Infect Dis 2016;18:442-5. [DOI: 10.1111/tid.12538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 115] [Article Influence: 12.1] [Reference Citation Analysis]
28 Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226-231. [PMID: 14742986 DOI: 10.1097/01.tp.0000101738.27552.9d] [Cited by in Crossref: 218] [Cited by in F6Publishing: 39] [Article Influence: 12.1] [Reference Citation Analysis]
29 Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev. 2010;CD006573. [PMID: 21154370 DOI: 10.1002/14651858.cd006573.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
30 Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol 2019;18:450-5. [PMID: 31028014 DOI: 10.1016/j.aohep.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Wellington J, Ma A, Kottilil S, Ravichandran B, Husson J, Bruno D, Wilson E. Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. Viruses 2021;13:1831. [PMID: 34578412 DOI: 10.3390/v13091831] [Reference Citation Analysis]
32 Bahra M, Neumann UP, Jacob D, Berg T, Neuhaus R, Langrehr JM, Neuhaus P. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl Int. 2007;20:771-778. [PMID: 17617179 DOI: 10.1111/j.1432-2277.2007.00517.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
33 Ueda Y, Takada Y, Marusawa H, Haga H, Sato T, Tanaka Y, Egawa H, Uemoto S, Chiba T. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. J Viral Hepat 2010;17:481-7. [PMID: 19804502 DOI: 10.1111/j.1365-2893.2009.01207.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Berenguer M, Wright TL. Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. Clinics in Liver Disease 2003;7:631-50. [DOI: 10.1016/s1089-3261(03)00059-x] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
35 Kosloski MP, Zhao W, Li H, Pugatch D, Asatryan A, Kort J, Mensa FJ, Liu W. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects. Clin Pharmacol Drug Dev 2019;8:779-89. [PMID: 30861340 DOI: 10.1002/cpdd.671] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
36 Hilgard P, Kahraman A, Lehmann N, Seltmann C, Beckebaum S, Ross RS, Baba HA, Malago M, Broelsch CE, Gerken G. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis. World J Gastroenterol 2006; 12(5): 697-702 [PMID: 16521181 DOI: 10.3748/wjg.v12.i5.697] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
37 Coilly A, Roche B, Duclos-vallée J, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014;34:46-52. [DOI: 10.1111/liv.12406] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
38 Peffault de Latour R, Lévy V, Asselah T, Marcellin P, Scieux C, Adès L, Traineau R, Devergie A, Ribaud P, Espérou H. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618-1624. [PMID: 14576071 DOI: 10.1182/blood-2003-06-2145] [Cited by in Crossref: 126] [Cited by in F6Publishing: 105] [Article Influence: 6.6] [Reference Citation Analysis]
39 Fasola CG, Klintmalm GB. Impact of immunosuppression in hepatitis C recurrence after liver transplantation: a controllable factor?: . Current Opinion in Organ Transplantation 2003;8:146-52. [DOI: 10.1097/00075200-200306000-00003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, Mueller NJ, Merville P, Emery V, Nashan B. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol 2013;23:97-125. [PMID: 23165654 DOI: 10.1002/rmv.1733] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
42 Saad WE, Davies MG, Lee DE, Patel NC, Sahler LG, Sasson T, Kitanososno T, Waldman DL. Transjugular Intrahepatic Portosystemic Shunt in a Living Donor Left Lateral Segment Liver Transplant Recipient: Technical Considerations. Journal of Vascular and Interventional Radiology 2005;16:873-7. [DOI: 10.1097/01.rvi.0000157776.47580.f7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1-16. [PMID: 24372756 DOI: 10.1111/tid.12173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
44 Maluf DG, Edwards EB, Stravitz RT, Kauffman HM. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl. 2009;15:592-599. [PMID: 19479802 DOI: 10.1002/lt.21699] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
45 Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant. 2004;4:1133-1138. [PMID: 15196072 DOI: 10.1111/j.1600-6143.2004.00470.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
46 Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl. 2009;15:1126-1132. [PMID: 19718638 DOI: 10.1002/lt.21835] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
47 Kim HJ. [Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis]. Korean J Hepatol 2007;13:489-94. [PMID: 18159146 DOI: 10.3350/kjhep.2007.13.4.489] [Reference Citation Analysis]
48 Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, Schönemann C, Krenn V, Neuhaus P, Neumann UP. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2006;12:644-651. [PMID: 16555324 DOI: 10.1002/lt.20648] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
49 Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization: Drop-Out Rates for HCC. Liver Transpl 2004;10:449-55. [DOI: 10.1002/lt.20099] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 9.3] [Reference Citation Analysis]
50 Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8:S28-S37. [PMID: 12362295 DOI: 10.1053/jlts.2002.35860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
51 Rubin A, Berenguer M. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there! Liver Transpl 2010;16:697-700. [PMID: 20517902 DOI: 10.1002/lt.22090] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005;9:579-600, vi. [PMID: 16207565 DOI: 10.1016/j.cld.2005.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
54 Fried MW, Kroner BL, Preiss LR, Wilhelmsen K, Goedert JJ; Multicenter Hemophilia Cohort Study. Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. Gastroenterology 2006;131:757-64. [PMID: 16952545 DOI: 10.1053/j.gastro.2006.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
55 Roche B, Samuel D. Steroid use in HCV-infected liver transplant recipients. Nat Rev Gastroenterol Hepatol 2009;6:198-200. [DOI: 10.1038/nrgastro.2009.38] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
56 Bahr MJ, Rosenau J, Manns MP. Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;123:2160. [DOI: 10.1053/gast.2002.37303b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int 2018;38:1188-97. [PMID: 29197145 DOI: 10.1111/liv.13652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:805-812. [PMID: 21963086 DOI: 10.1016/j.clinre.2011.04.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
59 Carbone M, Neuberger J. Liver transplantation for hepatitis C and alcoholic liver disease. J Transplant. 2010;2010:893893. [PMID: 21209701 DOI: 10.1155/2010/893893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
60 Lucey M. Induction immunosuppression in hepatitis C virus–infected liver transplant recipients. Liver Transplantation 2002;8:S44-6. [DOI: 10.1053/jlts.2002.35854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Marubashi S, Dono K, Nagano H, Kim C, Asaoka T, Hama N, Kobayashi S, Takeda Y, Umeshita K, Monden M, Doki Y, Mori M. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clinical Transplantation 2009;23:904-13. [DOI: 10.1111/j.1399-0012.2009.01022.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
62 Burra P, Belli LS, Ginanni Corradini S, Volpes R, Marzioni M, Giannini E, Toniutto P. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017;49:241-53. [PMID: 28096056 DOI: 10.1016/j.dld.2016.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
63 Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation. 2006;82:43-47. [PMID: 16861940 DOI: 10.1097/01.tp.0000225827.18034.be] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
64 O'Leary JG, Trotter JF, Neri MA, Jennings LW, McKenna GJ, Davis GL, Klintmalm GB. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Bayl Univ Med Cent) 2011;24:187-91. [PMID: 21738288 DOI: 10.1080/08998280.2011.11928712] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
65 Tasdogan BE, Akosman S, Gurakar M, Simsek C, Gurakar A. Update on Liver Transplantation: What is New Recently? Euroasian J Hepatogastroenterol 2019;9:34-9. [PMID: 31988865 DOI: 10.5005/jp-journals-10018-1293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, Marcos A, Demetris A, Jain A, Fung JJ. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983-2993. [PMID: 17062005 DOI: 10.1111/j.1600-6143.2006.01546.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
67 Shankar A, Alexander G. Liver transplantation for liver disease caused by hepatitis C virus infection. Br J Hosp Med (Lond) 2009;70:95-100. [PMID: 19229150 DOI: 10.12968/hmed.2009.70.2.38908] [Reference Citation Analysis]
68 Di Maira T, Rubin A, Puchades L, Aguilera V, Vinaixa C, Garcia M, De Maria N, Villa E, Lopez-Andujar R, San Juan F, Montalva E, Perez J, Prieto M, Berenguer M. Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. Liver Transpl. 2015;21:812-822. [PMID: 27396823 DOI: 10.1002/lt.24128] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
69 Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003;124:642-650. [PMID: 12612903 DOI: 10.1053/gast.2003.50095] [Cited by in Crossref: 282] [Cited by in F6Publishing: 250] [Article Influence: 14.8] [Reference Citation Analysis]
70 Yoshizawa A, Takada Y, Fujimoto Y, Koshiba T, Haga H, Nabeshima S, Uemoto S. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant. 2006;6:2812-2816. [PMID: 16939511 DOI: 10.1111/j.1600-6143.2006.01531.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
71 Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation. 2004;78:955-963. [PMID: 15480158 DOI: 10.1097/01.tp.0000140927.63952.58] [Cited by in Crossref: 39] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
72 Bitetto D, De Feo T, Mantovani M, Falleti E, Fabris C, Belli LS, Fagiuoli S, Burra P, Piccolo G, Donato MF. Interaction between calcineurin inhibitors and IL-28B rs12979860 C& gt; T polymorphism and response to treatment for post-transplant recurrent hepatitis C. Dig Liver Dis. 2013;45:927-932. [PMID: 23722013 DOI: 10.1016/j.dld.2013.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
73 Cross TJS, Calvaruso V, Foxton MR, Manousou P, Quaglia A, Grillo F, Dhillon AP, Nolan J, Chang TP, O’grady J, Heneghan MA, O’beirne JP, Burroughs AK, Harrison PM. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation: Noninvasive test for hepatitis C-related fibrosis post-LT. Journal of Viral Hepatitis 2010;17:640-9. [DOI: 10.1111/j.1365-2893.2009.01222.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
74 Åberg F, Nordin A, Toivonen L, Isoniemi H. Early Predictors of Long-term Outcomes of HCV-negative Liver Transplant Recipients Having Survived the First Postoperative Year. Transplantation 2016;100:382-90. [PMID: 26683515 DOI: 10.1097/TP.0000000000001038] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Wells M, Croome KM, Janik T, Hernandez-Alejandro RM, Chandok NM. Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis. Can J Gastroenterol Hepatol 2014;28:103-8. [PMID: 24288695 DOI: 10.1155/2014/421451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
76 Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia. 2010;26:448-455. [PMID: 20433313 DOI: 10.3109/02656731003717574] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
77 Gelley F, Gámán G, Gerlei Z, Zádori G, Görög D, Kóbori L, Fehérvári I, Schuller J, Szőnyi L, Nagy P, Doros A, Fazakas J, Lengyel G, Schaff Z, Kiss A, Sárváry E, Nemes B. Hepatitis C virus recurrence after liver transplantation in Hungary. Trends over the past 10 years. Orvosi Hetilap 2013;154:1058-66. [DOI: 10.1556/oh.2013.29647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Toniutto P, Fabris C, Bitetto D, Fornasiere E, Fumolo E, Rapetti R, Pirisi M. Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation. Ther Clin Risk Manag 2008;4:599-603. [PMID: 18827855 DOI: 10.2147/tcrm.s2661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Foruny JR, Bárcena R, Moreno A, Blázquez J, Manzano R, Gil-grande LA, Moreno A, Nuño J. Benefit of Pegylated Interferon-α-2a/Ribavirin in a Patient with Common Variable Immunodeficiency and Hepatitis C Virus Cirrhosis after Liver Transplantation and Splenic Embolization. Transplantation 2006;82:289-90. [DOI: 10.1097/01.tp.0000226223.95971.e7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
80 Russo MW, Shrestha R. Reporting outcomes on living donor liver transplant. Liver Transpl 2005;11:244-244. [DOI: 10.1002/lt.20324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Testino G, Vignoli T, Patussi V, Scafato E, Caputo F; SIA board (Appendix A) and the external expert supervisors (Appendix B). Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020;52:21-32. [PMID: 31757596 DOI: 10.1016/j.dld.2019.09.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
82 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 11.8] [Reference Citation Analysis]
83 Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Kurosaki M, Izumi N. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144-150. [PMID: 25338946 DOI: 10.1002/jhbp.171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
84 Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO. Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient. Mayo Clin Proc 2015;90:1294-7. [PMID: 26231293 DOI: 10.1016/j.mayocp.2015.06.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
85 Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61:S120-S131. [PMID: 25443340 DOI: 10.1016/j.jhep.2014.07.020] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
86 Burroughs A. Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no! Liver Transplantation 2002;8:S47-9. [DOI: 10.1053/jlts.2002.35853] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
87 Hong Z, Smart G, Dawood M, Kaita K, Wen S, Gomes J, Wu J. Hepatitis C Infection and Survivals of Liver Transplant Patients in Canada, 1997–2003. Transplantation Proceedings 2008;40:1466-70. [DOI: 10.1016/j.transproceed.2008.03.089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
88 Shiffman ML. Treating chronic hepatitis C virus after liver transplantation: Balancing the risks against the chance for success. Liver Transpl 2007;13:1088-91. [DOI: 10.1002/lt.21190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
89 Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano M, Lenci I, Bhoori S, Pieri G, Berardi S, Caraceni P, Martini S; ITACOPS-SOF Bridging Study Group. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Liver Int 2017;37:678-83. [PMID: 27865034 DOI: 10.1111/liv.13322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
90 Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 2004;40:669-674. [PMID: 15030984 DOI: 10.1016/j.jhep.2003.12.015] [Cited by in Crossref: 184] [Cited by in F6Publishing: 162] [Article Influence: 10.2] [Reference Citation Analysis]
91 Allen AM, Hay JE. Review article: the management of cirrhosis in women. Aliment Pharmacol Ther 2014;40:1146-54. [PMID: 25263269 DOI: 10.1111/apt.12974] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
92 von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, Mckeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006;43:932-42. [DOI: 10.1002/hep.21139] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 6.1] [Reference Citation Analysis]
93 Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830-836. [PMID: 15519657 DOI: 10.1016/j.jhep.2004.06.029] [Cited by in Crossref: 281] [Cited by in F6Publishing: 246] [Article Influence: 16.5] [Reference Citation Analysis]
94 Manousou P, Samonakis D, Cholongitas E, Patch D, O'beirne J, Dhillon AP, Rolles K, Mccormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy: Randomized Immunosuppression for Recurrent HCV. Liver Transpl 2009;15:1783-91. [DOI: 10.1002/lt.21907] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
95 Sugawara Y, Tamura S, Yamashiki N, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation. Transplant Proc. 2012;44:791-793. [PMID: 22483497 DOI: 10.1016/j.transproceed.2012.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
96 Daniel KE, Eickhoff J, Lucey MR. Why do patients die after a liver transplantation? Clin Transplant. 2017;31. [PMID: 28039946 DOI: 10.1111/ctr.12906] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
97 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
98 Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003;9:S101-8. [PMID: 14586904 DOI: 10.1053/jlts.2003.50250] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
99 O'Leary JG, Randall H, Onaca N, Jennings L, Klintmalm GB, Davis GL. Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl 2009;15:360-8. [PMID: 19326409 DOI: 10.1002/lt.21691] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
100 Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harnois DM, Crook JE, Steers JL, Dickson RC. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92. [PMID: 14724440 DOI: 10.1097/01.TP.0000095896.07048.BB] [Cited by in Crossref: 126] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
101 Zhou P, Liang P, Yu X, Wang Y, Dong B. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. 2009;13:318-324. [PMID: 18825464 DOI: 10.1007/s11605-008-0710-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
102 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 246] [Article Influence: 16.3] [Reference Citation Analysis]
103 Castells L. [Viral hepatitides infections in transplant recipients]. Enferm Infecc Microbiol Clin 2006;24:118-28. [PMID: 16545319 DOI: 10.1157/13085018] [Reference Citation Analysis]
104 Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatol Int. 2015;9:76-83. [PMID: 25788382 DOI: 10.1007/s12072-014-9589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post- transplant hepatitis C recurrence. Liver Int. 2015;35:2433-2441. [PMID: 26058570 DOI: 10.1111/liv.12890] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
106 Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl. 2011;17 Suppl 3:S20-S23. [PMID: 21850693 DOI: 10.1002/lt.22414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
107 Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, Monden M. Liver transplantation for hepatitis C. J Hepatobiliary Pancreat Surg 2006;13:382-92. [DOI: 10.1007/s00534-005-1078-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ghabril M, Dickson RC, Krishna M, Machicao V, Aranda-Michel J, Bonatti H, Nguyen JH. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transpl. 2011;17:685-694. [PMID: 21618689 DOI: 10.1002/lt.22250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
109 Mukherjee S, Lyden E, Mccashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: Cohort study of 38 patients. J Gastroenterol Hepatol 2005;20:198-203. [DOI: 10.1111/j.1400-1746.2004.03483.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
110 Tanaka T, Voigt MD. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database. J Hepatobiliary Pancreat Sci 2019;26:393-400. [PMID: 31211912 DOI: 10.1002/jhbp.645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Carrión JA, Torres F, Crespo G, Miquel R, García-valdecasas J, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010;51:23-34. [DOI: 10.1002/hep.23240] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
112 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
113 Moon DB, Lee SG. Liver transplantation. Gut Liver. 2009;3:145-165. [PMID: 20431740 DOI: 10.5009/gnl.2009.3.3.145] [Cited by in Crossref: 54] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
114 Wieland A, Everson GT. Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? Alcohol Alcohol 2018;53:187-92. [PMID: 29329373 DOI: 10.1093/alcalc/agx101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
115 Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, Eguchi S, Takatsuki M, Ikeda M, Yamasaki H. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl. 2008;14:292-298. [PMID: 18306331 DOI: 10.1002/lt.21358] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
116 Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation. 2007;84:829-835. [PMID: 17984834 DOI: 10.1097/01.tp.0000282914.20578.7b] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
117 Martini S, Sacco M, Strona S, Arese D, Tandoi F, Dell Olio D, Stradella D, Cocchis D, Mirabella S, Rizza G, Magistroni P, Moschini P, Ottobrelli A, Amoroso A, Rizzetto M, Salizzoni M, Saracco GM, Romagnoli R. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int 2017;37:62-70. [PMID: 27344058 DOI: 10.1111/liv.13193] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
118 Schmidt-Martin D, Elsharkawy AM. Editorial: is ribavirin needed in the treatment of post-transplant hepatitis C recurrence? Aliment Pharmacol Ther 2017;46:197-8. [PMID: 28621075 DOI: 10.1111/apt.14110] [Reference Citation Analysis]
119 Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat 2015;22:175-83. [PMID: 25040391 DOI: 10.1111/jvh.12278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
120 Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013;33:56-62. [DOI: 10.1111/liv.12062] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
121 Alqahtani SA. Update in liver transplantation. Curr Opin Gastroenterol. 2012;28:230-238. [PMID: 22450898 DOI: 10.1097/mog.0b013e3283527f16] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
122 Castedal M, Segenmark M, Cederberg S, Skoglund C, Weiland O. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. Scand J Gastroenterol 2017;52:585-8. [PMID: 28270038 DOI: 10.1080/00365521.2017.1283439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
123 Quintini C, Hashimoto K, Uso TD, Miller C. Is there an advantage of living over deceased donation in liver transplantation? Transpl Int 2013;26:11-9. [PMID: 22937787 DOI: 10.1111/j.1432-2277.2012.01550.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
124 Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, Detre K, Wei Y, Everhart J. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004;10:1120-1130. [PMID: 15350002 DOI: 10.1002/lt.20211] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
125 Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007;13:733-740. [PMID: 17370330 DOI: 10.1002/lt.21093] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
126 Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012;18:514-523. [PMID: 22315212 DOI: 10.1002/lt.23408] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
127 Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR, Peyton A. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823-830. [PMID: 25825070 DOI: 10.1002/lt.24126] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 13.5] [Reference Citation Analysis]
128 Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, Minisini R, Pirisi M. Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol. 2005;20:577-582. [PMID: 15836706 DOI: 10.1111/j.1440-1746.2005.03795.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
129 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transplant Int 2004;17:759-66. [DOI: 10.1111/j.1432-2277.2004.tb00508.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
130 Chu HC, Hsieh CB, Hsu KF, Fan HL, Hsieh TY, Chen TW. Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus. Am J Surg 2015;209:180-6. [PMID: 24928331 DOI: 10.1016/j.amjsurg.2014.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
131 Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl. 2003;9:1129-1144. [PMID: 14586872 DOI: 10.1053/jlts.2003.50261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
132 Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006;12:1067-1076. [PMID: 16622844 DOI: 10.1002/lt.20737] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 8.4] [Reference Citation Analysis]
133 Arenas JI, Vargas HE. Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterology Clinics of North America 2004;33:549-62. [DOI: 10.1016/j.gtc.2004.04.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
134 Benlloch S, Berenguer M, Prieto M, Rayón JM, Aguilera V, Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl. 2005;11:456-462. [PMID: 15776403 DOI: 10.1002/lt.20381] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
135 Mccashland TM. Retransplantation for recurrent hepatitis C: Positive aspects. Liver Transplantation;9:S67-72. [DOI: 10.1053/jlts.2003.50249] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
136 Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol 2014; 20(44): 16409-16417 [PMID: 25469009 DOI: 10.3748/wjg.v20.i44.16409] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
137 Caputo F, Testino G. Orthotopic liver transplantation for patients with end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis. Minerva Surg 2021;76:444-9. [PMID: 33433074 DOI: 10.23736/S2724-5691.20.08685-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:183-97. [DOI: 10.1016/s1542-3565(04)00002-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
139 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01226-X. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Reference Citation Analysis]
140 Kuo A, Terrault NA. Is recurrent hepatitis C worse with living donors? Current Opinion in Organ Transplantation 2009;14:240-4. [DOI: 10.1097/mot.0b013e32832b1f1d] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
141 Layden JE, Cotler SJ, Grim SA, Fischer MJ, Lucey MR, Clark NM. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation. 2012;93:444-449. [PMID: 22277982 DOI: 10.1097/tp.0b013e3182406a94] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
142 Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, Hasegawa K, Sakamoto Y, Kokudo N. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation: DAA for HCV-infected LDLT recipient. Hepatol Res 2017;47:1093-101. [DOI: 10.1111/hepr.12845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
143 Huprikar S. Update in Infectious Diseases in Liver Transplant Recipients. Clinics in Liver Disease 2007;11:337-54. [DOI: 10.1016/j.cld.2007.04.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
144 Feng AC, Chen TW, Fan HL, Yu JC, Hsieh CB. The Correlation of Hepatic and Systemic Hemodynamics During Liver Transplantation: Quantification of Hepatic Resistance as an Actual Value. Medicine (Baltimore) 2015;94:e1815. [PMID: 26512581 DOI: 10.1097/MD.0000000000001815] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, Sanyal AJ, Cotterell A, Maluf D, Posner MP. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl. 2004;10:1248-1255. [PMID: 15376308 DOI: 10.1002/lt.20232] [Cited by in Crossref: 113] [Cited by in F6Publishing: 92] [Article Influence: 6.6] [Reference Citation Analysis]
146 Sibulesky L, Nguyen JH, Paz-Fumagalli R, Taner CB, Dickson RC. Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C. World J Gastroenterol 2009; 15(40): 5010-5013 [PMID: 19859992 DOI: 10.3748/wjg.15.5010] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
147 Filipec Kanizaj T, Kunac N. Hepatitis C: New challenges in liver transplantation. World J Gastroenterol 2015; 21(19): 5768-5777 [PMID: 26019441 DOI: 10.3748/wjg.v21.i19.5768] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Lucidi V, Gustot T, Moreno C, Donckier V. Liver transplantation in the context of organ shortage: toward extension and restriction of indications considering recent clinical data and ethical framework. Curr Opin Crit Care 2015;21:163-70. [PMID: 25692807 DOI: 10.1097/MCC.0000000000000186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
149 Singal AK, Hmoud BS, Guturu P, Kuo YF. Outcome after liver transplantation for cirrhosis due to alcohol and hepatitis C: comparison to alcoholic cirrhosis and hepatitis C cirrhosis. J Clin Gastroenterol. 2013;47:727-733. [PMID: 23751845 DOI: 10.1097/mcg.0b013e318294148d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
150 Burton JR, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014;61:508-514. [PMID: 24801415 DOI: 10.1016/j.jhep.2014.04.037] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 8.4] [Reference Citation Analysis]
151 Lengyel G, Tulassay Z. [Treatment of recurrent hepatitis C virus infection after liver transplantation]. Orv Hetil 2007;148:1875-81. [PMID: 17905682 DOI: 10.1556/OH.2007.28217] [Reference Citation Analysis]
152 Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA; Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C genotype influences post-liver transplant outcomes. Transplantation 2015;99:835-40. [PMID: 25211520 DOI: 10.1097/TP.0000000000000413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
153 Agarwal K, Barnabas A. Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis. 2013;45 Suppl 5:S349-S354. [PMID: 24091115 DOI: 10.1016/j.dld.2013.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
154 Halpern SD, Asch DA, Shaked A, Stock PG, Blumberg E. Determinants of Transplant Surgeons' Willingness to Provide Organs to Patients Infected with HBV, HCV or HIV. Am J Transplant 2005;5:1319-25. [DOI: 10.1111/j.1600-6143.2005.00812.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
155 Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 2012;18:671-679. [PMID: 22298465 DOI: 10.1002/lt.23402] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
156 Jesudian A, Desale S, Julia J, Landry E, Maxwell C, Kallakury B, Laurin J, Shetty K. Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C Virus. J Clin Exp Hepatol 2016;6:109-14. [PMID: 27493458 DOI: 10.1016/j.jceh.2015.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
157 Said A, Lucey MR. Liver transplantation: an update. Curr Opin Gastroenterol. 2006;22:272-278. [PMID: 16550042 DOI: 10.1097/01.mog.0000218964.70935.3c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
158 Gao Z. Seeking Beyond Rejection: An Update on the Differential Diagnosis and a Practical Approach to Liver Allograft Biopsy Interpretation. Advances in Anatomic Pathology 2009;16:97-117. [DOI: 10.1097/pap.0b013e31819946aa] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, Souquet JC, Ducerf C, Baulieux J, Zoulim F. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant. 2005;5:1909-1913. [PMID: 15996238 DOI: 10.1111/j.1600-6143.2005.00976.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 82] [Article Influence: 5.5] [Reference Citation Analysis]
160 Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Curr Opin Organ Transplant 2018;23:257-63. [PMID: 29432255 DOI: 10.1097/MOT.0000000000000504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
161 Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation. 2014;98:216-221. [PMID: 24621538 DOI: 10.1097/tp.0000000000000048] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
162 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
163 Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101-110. [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
164 Barsa JE, Branch AD, Schiano TD. A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation? Clin Transplant 2015;29:859-65. [DOI: 10.1111/ctr.12596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
165 Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766-1777. [PMID: 19025933 DOI: 10.1002/lt.21635] [Cited by in Crossref: 114] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
166 Lai JC, Verna EC, Brown RS, O’Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418-424. [PMID: 21538434 DOI: 10.1002/hep.24390] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
167 Waki K, Sugawara Y, Tamura S, Mieno MN, Yamashiki N, Kadowaki T, Kokudo N. Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data. Transplantation 2011;92:809-14. [PMID: 21832961 DOI: 10.1097/TP.0b013e31822d4dc3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
168 Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase*. J Viral Hepat 2006;13:377-86. [DOI: 10.1111/j.1365-2893.2005.00700.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
169 Wall WJ, Khakhar A. Retransplantation for recurrent hepatitis C: The argument against. Liver Transplantation;9:S73-8. [DOI: 10.1053/jlts.2003.50258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
170 Rossi M, Mennini G, Lai Q, Ginanni Corradini S, Drudi FM, Pugliese F, Berloco PB. Liver transplantation(). J Ultrasound 2007;10:28-45. [PMID: 23396075 DOI: 10.1016/j.jus.2007.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Dantas LC, Genzini T, Miranda MP, Santos RG, Siqueira NG, Weirich J, Lobato CM. Liver transplantation in a patient with hepatitis B, C and D coinfection associated with hepatocellular carcinoma: a management strategy for a rare condition. Case report. Sao Paulo Med J 2015;133:525-30. [PMID: 26176835 DOI: 10.1590/1516-3180.2015.8881501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
172 Li M, Li Z, Yu X, Liang P, Gao Y, Han Z, Liu F, Dong J. Percutaneous radio-frequency ablation of hepatocellular carcinoma adjacent to the gastrointestinal tract. International Journal of Hyperthermia 2016;32:600-6. [DOI: 10.3109/02656736.2016.1157904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004;10:868-71. [PMID: 15237370 DOI: 10.1002/lt.20194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
174 Grassi A, Quarneti C, Ravaioli M, Bianchini F, Susca M, D’Errico A, Piscaglia F, Tamè MR, Andreone P, Grazi G. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 2006;12:1673-1681. [PMID: 17031825 DOI: 10.1002/lt.20882] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
175 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
176 Massaguer A, Ramírez S, Carrión JA, González P, Sánchez-Tapias JM, Forns X. Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am J Transplant 2007;7:2172-9. [PMID: 17608833 DOI: 10.1111/j.1600-6143.2007.01894.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
177 Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007;13:21-29. [PMID: 17192906 DOI: 10.1002/lt.21035] [Cited by in Crossref: 126] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
178 Kawaoka T, Imamura M, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Naeshiro N, Hiramatsu A, Tsuge M, Hayes CN, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Tashiro H, Ohdan H, Chayama K. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. Transplant Proc 2015;47:809-14. [PMID: 25891736 DOI: 10.1016/j.transproceed.2014.10.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
179 Verna EC, De Martin E, Burra P, Neri D, Gaglio PJ, Emond JC, Brown RS. The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation. Am J Transplant. 2009;9:1398-1405. [PMID: 19459805 DOI: 10.1111/j.1600-6143.2009.02649.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
180 Doucette KE, Weinkauf J, Sumner S, Ens K, Lien D. Treatment of hepatitis C in potential lung transplant candidates. Transplantation. 2007;83:1652-1655. [PMID: 17589352 DOI: 10.1097/01.tp.0000264561.18380.22] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
181 Walker MP, Yao N, Hong Z. Promising candidates for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2003;12:1269-80. [PMID: 12882616 DOI: 10.1517/13543784.12.8.1269] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
182 Donckier V, Lucidi V, Gustot T, Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol. 2014;60:866-871. [PMID: 24291238 DOI: 10.1016/j.jhep.2013.11.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
183 Campos-Varela I, Agudelo EZ, Terrault NA. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series. Clin Transplant 2018;32:e13303. [PMID: 29851150 DOI: 10.1111/ctr.13303] [Reference Citation Analysis]
184 Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2004;41:2-10. [PMID: 15246200 DOI: 10.1016/j.jhep.2004.04.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
185 Kuo A, Terrault NA. Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters? Journal of Hepatology 2007;46:359-61. [DOI: 10.1016/j.jhep.2006.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
186 Takeishi K, Shirabe K, Toshima T, Ikegami T, Morita K, Fukuhara T, Motomura T, Mano Y, Uchiyama H, Soejima Y. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. Surg Today. 2011;41:1016-1019. [PMID: 21748625 DOI: 10.1007/s00595-010-4392-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
187 Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, Garcia-Valdecasas JC, Salizzoni M, Moreno GE, Mirza D. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation. 2006;81:7-14. [PMID: 16421468 DOI: 10.1097/01.tp.0000188619.30677.84] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 7.8] [Reference Citation Analysis]
188 Melero JL, Berenguer M. Optimum minimization strategies in hepatitis C virus infected liver transplant: . Current Opinion in Organ Transplantation 2007;12:641-6. [DOI: 10.1097/mot.0b013e3282f1fbd9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Tronina O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M, Lisik W, Kosieradzki M, Durlik M. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplant Proc 2017;49:1409-18. [PMID: 28736015 DOI: 10.1016/j.transproceed.2017.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
190 Takada Y, Haga H, Ito T, Nabeshima M, Ogawa K, Kasahara M, Oike F, Ueda M, Egawa H, Tanaka K. Clinical Outcomes of Living Donor Liver Transplantation for Hepatitis C Virus (HCV)-Positive Patients: . Transplantation 2006;81:350-4. [DOI: 10.1097/01.tp.0000197554.16093.d1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
191 Dutkowski P, Linecker M, Deoliveira ML, Müllhaupt B, Clavien P. Challenges to Liver Transplantation and Strategies to Improve Outcomes. Gastroenterology 2015;148:307-23. [DOI: 10.1053/j.gastro.2014.08.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 134] [Article Influence: 19.3] [Reference Citation Analysis]
192 Davis GL, Krawczynski K, Szabo G. Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options. Dig Dis Sci 2007;52:857-75. [DOI: 10.1007/s10620-006-9484-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
193 Nakamura J, Toyabe S, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 2008;15:293-9. [DOI: 10.1111/j.1365-2893.2007.00943.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
194 Yoshida R, Iwamoto T, Yagi T, Sato D, Umeda Y, Mizuno K, Shinoura S, Matsukawa H, Matsuda H, Sadamori H. Preoperative assessment of the risk factors that help to predict the prognosis after living donor liver transplantation. World J Surg. 2008;32:2419-2424. [PMID: 18795246 DOI: 10.1007/s00268-008-9715-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
195 Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:199-207. [PMID: 14762857 DOI: 10.1002/lt.20074] [Cited by in Crossref: 124] [Cited by in F6Publishing: 112] [Article Influence: 6.9] [Reference Citation Analysis]
196 Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl 2007;13:1017-27. [PMID: 17600343 DOI: 10.1002/lt.21178] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
197 Ichikawa T, Nakao K, Miyaaki H, Eguchi S, Takatsuki M, Fujimito M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Kanematsu T, Eguchi K. Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation. Hepatol Res 2009;39:856-64. [PMID: 19624776 DOI: 10.1111/j.1872-034X.2009.00524.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
198 Bachir NM, Larson AM. Adult liver transplantation in the United States. Am J Med Sci. 2012;343:462-469. [PMID: 22683615 DOI: 10.1097/maj.0b013e3182308b66] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
199 Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, Strassburg CP, Manns MP. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc. 2005;37:1703-1704. [PMID: 15919437 DOI: 10.1016/j.transproceed.2005.02.103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
200 Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-55. [PMID: 16869810 DOI: 10.1111/j.1600-6143.2006.01470.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 86] [Article Influence: 6.8] [Reference Citation Analysis]
201 Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transpl. 2009;15:79-87. [PMID: 19109849 DOI: 10.1002/lt.21626] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
202 Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008;14:53-58. [PMID: 18161839 DOI: 10.1002/lt.21312] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
203 Fabien S, Olivier M, Khaldoun G, Vivian V, Lynda A, Laurissa O, Gautier G, Yvon C, Nadira D, Filomena C. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation. Biomed Res Int 2014;2014:290878. [PMID: 24575405 DOI: 10.1155/2014/290878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
204 Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492-499. [PMID: 16496308 DOI: 10.1002/hep.21090] [Cited by in Crossref: 220] [Cited by in F6Publishing: 199] [Article Influence: 13.8] [Reference Citation Analysis]
205 Pyrsopoulos N, Trilianos P, Lingiah VA, Fung P, Punnoose M. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Eur J Gastroenterol Hepatol 2018;30:761-5. [PMID: 29481384 DOI: 10.1097/MEG.0000000000001101] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
206 El-Meteini M, Sakr M, Eldorry A, Mohran Z, Abdelkader NA, Dabbous H, Montasser I, Refaie R, Salah M, Aly M. Non-Invasive Assessment of Graft Fibrosis After Living Donor Liver Transplantation: Is There Still a Role for Liver Biopsy? Transplant Proc 2019;51:2451-6. [PMID: 31358454 DOI: 10.1016/j.transproceed.2019.01.197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Lens S, Mariño Z, Forns X. Beyond the achievement of sustained virological response after liver transplantation. Liver Int 2015;35:2354-7. [PMID: 26189705 DOI: 10.1111/liv.12915] [Reference Citation Analysis]
208 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 292] [Article Influence: 55.7] [Reference Citation Analysis]
209 Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P, Ballardini G. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther. 2008;28:450-457. [PMID: 18549463 DOI: 10.1111/j.1365-2036.2008.03761.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
210 Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004;173:5355-9. [PMID: 15494481 DOI: 10.4049/jimmunol.173.9.5355] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
211 Biggins SW, Terrault NA. Management of Recurrent Hepatitis C in Liver Transplant Recipients. Infectious Disease Clinics of North America 2006;20:155-74. [DOI: 10.1016/j.idc.2006.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
212 Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-34. [PMID: 17111055 DOI: 10.1155/2006/238218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
213 Al-Judaibi B. The new era of hepatitis C virus therapy. Saudi J Gastroenterol 2015;21:345-54. [PMID: 26655128 DOI: 10.4103/1319-3767.170947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
214 Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014;21:397-404. [PMID: 24750545 DOI: 10.1111/jvh.12154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
215 Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H, Ghobrial RM, Farmer DG. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant. 2003;3:328-333. [PMID: 12614290 DOI: 10.1034/j.1600-6143.2003.00053.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
216 Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, Bansal M, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World J Gastroenterol 2016; 22(9): 2844-2854 [PMID: 26973423 DOI: 10.3748/wjg.v22.i9.2844] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
217 Burra P, Targhetta S, Pevere S, Boninsegna S, Guido M, Canova D, Brolese A, Masier A, D’aloiso C, Germani G, Tomat S, Fagiuoli S. Antiviral Therapy for Hepatitis C Virus Recurrence Following Liver Transplantation: Long-Term Results From a Single Center Experience. Transplantation Proceedings 2006;38:1127-30. [DOI: 10.1016/j.transproceed.2006.02.135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
218 Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-8. [DOI: 10.1002/lt.20857] [Cited by in Crossref: 300] [Cited by in F6Publishing: 274] [Article Influence: 18.8] [Reference Citation Analysis]
219 Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013;:CD006573. [PMID: 24297303 DOI: 10.1002/14651858.CD006573.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
220 Kornberg A, Küpper B, Tannapfel A, Hommann M, Scheele J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005;5:107-15. [PMID: 15589468 DOI: 10.1016/j.intimp.2004.09.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
221 Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. Journal of Hepatology 2011;55:207-17. [DOI: 10.1016/j.jhep.2010.11.012] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 7.1] [Reference Citation Analysis]
222 Dabbous HM, Montasser IF, Sakr MA, Refai R, Sayam M, Abdelmonem A, Sayed H, F Abdelghafar M, Bahaa M, S Elmeteini M. Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? Hepat Mon. 2016;16:e35339. [PMID: 27330537 DOI: 10.5812/hepatmon.35339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
223 Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M. A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Annals of Hepatology 2013;12:282-93. [DOI: 10.1016/s1665-2681(19)31367-5] [Cited by in Crossref: 11] [Article Influence: 1.2] [Reference Citation Analysis]
224 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Berenguer M. Viral hepatitis after liver transplantation. Hepatology Research 2007;37:S279-86. [DOI: 10.1111/j.1872-034x.2007.00198.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11:386-395. [PMID: 15776454 DOI: 10.1002/lt.20344] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
227 Kuo A, Terrault NA. Management of Hepatitis C in Liver Transplant Recipients: Management of Hepatitis C in Liver Transplant Recipients. American Journal of Transplantation 2006;6:449-58. [DOI: 10.1111/j.1600-6143.2005.01202.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
228 Berenguer M. [Management of hepatitis C virus infection in liver transplantation]. Gastroenterol Hepatol 2006;29:422-7. [PMID: 16938259 DOI: 10.1157/13091455] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
229 Chan S, Rosen H. Outcome and Management of Hepatitis C in Liver Transplant Recipients. CLIN INFECT DIS 2003;37:807-12. [DOI: 10.1086/377605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
230 Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3(7): 198-204 [PMID: 21866251 DOI: 10.4254/wjh.v3.i7.198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
231 Verna EC, Saxena V, Burton JR, O’Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015;99:1644-1651. [PMID: 25715116 DOI: 10.1097/tp.0000000000000629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
232 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
233 Dharancy S, Coilly A, Fougerou-Leurent C, Duvoux C, Kamar N, Leroy V, Tran A, Houssel-Debry P, Canva V, Moreno C, Conti F, Dumortier J, Di Martino V, Radenne S, De Ledinghen V, D'Alteroche L, Silvain C, Besch C, Perré P, Botta-Fridlund D, Francoz C, Habersetzer F, Montialoux H, Abergel A, Debette-Gratien M, Rohel A, Rossignol E, Samuel D, Duclos-Vallée JC, Pageaux GP; ANRS CO23 CUPILT study group. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. Am J Transplant 2017;17:2869-78. [PMID: 28898563 DOI: 10.1111/ajt.14490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
234 Rimola A, Londoño MC, Guevara G, Bruguera M, Navasa M, Forns X, García-Retortillo M, García-Valdecasas JC, Rodes J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78:686-91. [PMID: 15371669 DOI: 10.1097/01.tp.0000128913.09774.ce] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
235 Berenguer M. Management of Hepatitis C Virus in the Transplant Patient. Clinics in Liver Disease 2007;11:355-76. [DOI: 10.1016/j.cld.2007.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
236 Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 2007;13:975-983. [PMID: 17600360 DOI: 10.1002/lt.21117] [Cited by in Crossref: 107] [Cited by in F6Publishing: 95] [Article Influence: 7.1] [Reference Citation Analysis]
237 Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577-1585, 1585.e1-3. [PMID: 20708617 DOI: 10.1053/j.gastro.2010.07.058] [Cited by in Crossref: 173] [Cited by in F6Publishing: 160] [Article Influence: 14.4] [Reference Citation Analysis]
238 Feng S. Increased donor risk: Who should bear the burden? Liver Transpl 2009;15:570-3. [DOI: 10.1002/lt.21790] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
239 Kwo P, Agrawal S. Treating hepatitis C virus in patients with decompensated cirrhosis: Why is it so difficult and does a sustained response rate rescue the patient from liver transplantation? Clin Liver Dis (Hoboken) 2015;6:133-5. [PMID: 31041009 DOI: 10.1002/cld.519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
240 Edeghere O, Verlander NQ, Aboulhab J, Costella A, Harris HE, Balogun MA, Ramsay ME. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection. Public Health 2015;129:509-16. [PMID: 25726124 DOI: 10.1016/j.puhe.2015.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Rodríguez-Framil M, Otero-Antón E, Tomé-Martínez de Rituerto S, González-Quintela A, Fernández-Castroagudín J, Varo-Pérez E. [Influence of donor age and recipient gender on survival in transplantation due to hepatocarcinoma]. Gastroenterol Hepatol 2008;31:293-4. [PMID: 18448059 DOI: 10.1157/13119882] [Reference Citation Analysis]
242 Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006;44:717-722. [PMID: 16487616 DOI: 10.1016/j.jhep.2006.01.005] [Cited by in Crossref: 131] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
243 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 116.3] [Reference Citation Analysis]
244 Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586-1599. [PMID: 16827859 DOI: 10.1111/j.1600-6143.2006.01362.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 126] [Article Influence: 9.3] [Reference Citation Analysis]
245 Uemura T, Ramprasad V, Hollenbeak CS, Bezinover D, Kadry Z. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12:984-991. [PMID: 22225523 DOI: 10.1111/j.1600-6143.2011.03899.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
246 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
247 Tremosini S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis. 2010;42 Suppl 3:S242-S248. [PMID: 20547310 DOI: 10.1016/s1590-8658(10)60512-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
248 Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post–liver transplant survival in patients with hepatitis C between 1991 and 2001 in the united states. Liver Transpl 2007;13:719-24. [DOI: 10.1002/lt.21123] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
249 Tran TT, Nissen N, Poordad FF, Martin P. Advances in liver transplantation. New strategies and current care expand access, enhance survival. Postgrad Med 2004;115:73-6, 79-85. [PMID: 15171080 DOI: 10.3810/pgm.2004.05.1514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
250 Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M. Unexpected maintenance of hepatitis C viral diversity following liver transplantation. J Virol. 2012;86:8432-8439. [PMID: 22623804 DOI: 10.1128/jvi.00749-12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
251 Fabris C, Toniutto P, Bitetto D, Minisini R, Fornasiere E, Smirne C, Pirisi M. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation. J Gastroenterol. 2007;42:543-549. [PMID: 17653650 DOI: 10.1007/s00535-007-2040-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
252 Fernandes F, Poole DS, Hoover S, Middleton R, Andrei AC, Gerstner J, Striker R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology. 2007;46:1026-1033. [PMID: 17600342 DOI: 10.1002/hep.21809] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 5.7] [Reference Citation Analysis]
253 Berenguer M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl. 2007;13:641-643. [PMID: 17457858 DOI: 10.1002/lt.21136] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
254 Nanmoku K, Imaizumi R, Tojimbara T, Nakajima I, Fuchinoue S, Sakamoto N, Watanabe M, Teraoka S. Effects of Immunosuppressants on the Progression of Hepatitis C in Hepatitis C Virus-Positive Renal Transplantation and the Usefulness of Interferon Therapy. Transplantation Proceedings 2008;40:2382-5. [DOI: 10.1016/j.transproceed.2008.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
255 Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'errico-grigioni A, Golfieri R, Pinna AD. Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers. Transplantation 2011;91:1279-85. [DOI: 10.1097/tp.0b013e3182187cf0] [Cited by in Crossref: 77] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
256 Gaynor JJ, Moon JI, Kato T, Nishida S, Selvaggi G, Levi DM, Island ER, Pyrsopoulos N, Weppler D, Ganz S. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation. 2007;84:155-165. [PMID: 17667806 DOI: 10.1097/01.tp.0000269090.90068.0f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
257 Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35:281-289. [PMID: 25896946 DOI: 10.1007/s40261-015-0279-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
258 Kwo PY, Ghabril M, Lacerda MA, Joseph Tector A, Fridell JA, Vianna R. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clin Transplant 2014;28:722-7. [DOI: 10.1111/ctr.12372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
259 Yagci G, Fernandez LA, Knechtle SJ, D’Alessandro AM, Chin LT, Musat AI, Lucey MR, Said A, Pirsch JD, Leverson G. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc. 2008;40:219-223. [PMID: 18261591 DOI: 10.1016/j.transproceed.2007.11.058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
260 Layden JE, Tayo BO, Cotler SJ, Clark NM, Baraoidan K, Friedman SL, Cooper RS. Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation 2014;97:1072-8. [PMID: 24770613 DOI: 10.1097/01.TP.0000440953.06886.a3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Werner CR, Franz C, Egetemeyr DP, Janke-Maier P, Malek NP, Lauer UM, Berg CP. Efficacy and safety of telaprevir (TVR) triple therapy in a ‘real-life’ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat. 2014;21:333-340. [PMID: 24716636 DOI: 10.1111/jvh.12145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
262 Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311-8. [PMID: 15822034 DOI: 10.1016/s1542-3565(04)00666-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
263 Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scandinavian Journal of Gastroenterology 2010;45:1488-96. [DOI: 10.3109/00365521.2010.505657] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
264 Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent advances in liver transplantation. Mayo Clin Proc. 2003;78:197-210. [PMID: 12583530 DOI: 10.4065/78.2.197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
265 Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazec JY, Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl. 2007;13:294-301. [PMID: 17256784 DOI: 10.1002/lt.21000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
266 Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann JF. Survival following liver transplantation from non-heart-beating donors. Ann Surg. 2004;239:87-92. [PMID: 14685105 DOI: 10.1097/01.sla.0000103063.82181.2c] [Cited by in Crossref: 275] [Cited by in F6Publishing: 229] [Article Influence: 15.3] [Reference Citation Analysis]
267 Sprinzl MF, Otto G, Galle PR, Schuchmann M. Hepatitis C virus re-infection: new perspectives. Clin Transplant 2006;20 Suppl 17:117-23. [PMID: 17100711 DOI: 10.1111/j.1399-0012.2006.00610.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Mancuso A, Mazzola A, Cabibbo G, Perricone G, Enea M, Galvano A, Zavaglia C, Belli L, Cammà C. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis 2015;47:324-30. [PMID: 25641331 DOI: 10.1016/j.dld.2015.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
269 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
270 Safwan M, Nwagu U, Collins K, Abouljoud M, Nagai S. Should All Status 1A Patients Be Prioritized Over High MELD Patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients. Transplantation 2019;103:2121-9. [DOI: 10.1097/tp.0000000000002651] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
271 Kim KA. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment]. Korean J Gastroenterol 2016;67:123-6. [PMID: 26996180 DOI: 10.4166/kjg.2016.67.3.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
272 Bertuzzo VR, Cescon M, Morelli MC, Di Gioia P, Tamè M, Lorenzini S, Andreone P, Ercolani G, Del Gaudio M, Ravaioli M. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation. Dig Liver Dis. 2012;44:861-867. [PMID: 22819767 DOI: 10.1016/j.dld.2012.06.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
273 Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 2012;8:e1002895. [PMID: 22952447 DOI: 10.1371/journal.ppat.1002895] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 11.5] [Reference Citation Analysis]
274 Hanouneh IA, Zein NN, Lopez R, Yerian L, Fung J, Eghtesad B. IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens. Int J Organ Transplant Med. 2010;1:7-14. [PMID: 25013557 DOI: 10.1016/s0016-5085(08)63573-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
275 Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756. [PMID: 17484872 DOI: 10.1053/j.gastro.2007.03.041] [Cited by in Crossref: 287] [Cited by in F6Publishing: 241] [Article Influence: 19.1] [Reference Citation Analysis]
276 Desai NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW, Velidedeoglu E, Chapman WC, Markmann JF. Predicting outcome after liver transplantation: Utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation. 2004;77:99-106. [PMID: 14724442 DOI: 10.1097/01.tp.0000101009.91516.fc] [Cited by in Crossref: 201] [Cited by in F6Publishing: 39] [Article Influence: 11.2] [Reference Citation Analysis]
277 Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res. 2011;41:328-339. [PMID: 21426450 DOI: 10.1111/j.1872-034x.2011.00781.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
278 Jackson WE, Hanouneh M, Apfel T, Alkhouri N, John BV, Zervos X, Zein NN, Hanouneh IA. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016;30:709-713. [PMID: 27019204 DOI: 10.1111/ctr.12738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
279 Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis. 2004;17:363-371. [PMID: 15241083 DOI: 10.1097/01.qco.0000136934.06039.01] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
280 Mccaughan GW, Shackel NA, Strasser SI, Dilworth P, Tang P; on The behalf of The Australian and New Zealand Liver Transplant Study Group. Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark. Liver Transpl 2010;16:130-7. [DOI: 10.1002/lt.21978] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
281 Ciccorossi P, Maina AM, Oliveri F, Petruccelli S, Leandro G, Colombatto P, Moriconi F, Mosca F, Filipponi F, Bonino F, Brunetto MR. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007;27:612-9. [DOI: 10.1111/j.1478-3231.2007.01459.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
282 Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA;  Hepatitis C Therapeutic Registry Research Network Study Group. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22:24-33. [PMID: 26519873 DOI: 10.1002/lt.24366] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 15.5] [Reference Citation Analysis]
283 Terrault NA, Pessoa MG. Pre- and Posttransplant Management of Hepatitis C. In: Trotter JF, Everson GT, editors. Liver Transplantation. Totowa: Humana Press; 2009. pp. 45-63. [DOI: 10.1007/978-1-60327-028-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
284 Audet M, Piardi T, Cag M, Navarro F, Ornis S, Cinqualbre J, Wolf P, Panaro F. Hepatitis C recurrence after liver transplantation: has the human leukocyte antigen mismatching at individual loci a role? J Gastroenterol Hepatol. 2011;26:1772-1778. [PMID: 22097939 DOI: 10.1111/j.1440-1746.2011.06772.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
285 Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment: . Current Opinion in Organ Transplantation 2005;10:81-9. [DOI: 10.1097/01.mot.0000161761.40866.12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
286 Hu Z, Zhou J, Wang H, Zhang M, Li S, Huang Y, Wu J, Li Z, Zhou L, Zheng S. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One. 2013;8:e61620. [PMID: 23613886 DOI: 10.1371/journal.pone.0061620] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
287 Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006;82:579-80. [PMID: 16926607 DOI: 10.1097/01.tp.0000229397.81425.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
288 Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Management of post transplant hepatitis C in the direct antiviral agents era. Hepatol Int 2015;9:192-201. [PMID: 25820797 DOI: 10.1007/s12072-015-9621-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
289 Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant. 2011;11:1773-1784. [PMID: 21672146 DOI: 10.1111/j.1600-6143.2011.03587.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 10.0] [Reference Citation Analysis]
290 Brown K. Maximizing donors with viral hepatitis in the current era. Liver Transpl 2017;23:S44-9. [PMID: 28846183 DOI: 10.1002/lt.24863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
291 Burra P, De Martin E, Zanetto A, Senzolo M, Russo FP, Zanus G, Fagiuoli S. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int 2016;29:135-52. [DOI: 10.1111/tri.12642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
292 Tamura S, Sugawara Y. Treatment strategy for hepatitis C after liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:111-23. [DOI: 10.1007/s00534-007-1295-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
293 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
294 Chan C, Schiano T, Agudelo E, Paul Haydek J, Hoteit M, Laurito MP, Norvell JP, Terrault N, Verna EC, Yang A, Levitsky J. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. Am J Transplant. 2018;18:2506-2512. [PMID: 30075485 DOI: 10.1111/ajt.15053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
295 Ueda Y, Uemoto S. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation 2016;100:54-60. [PMID: 26335914 DOI: 10.1097/TP.0000000000000860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
296 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
297 Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry MP, Fagiuoli S. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017;101:956-967. [PMID: 28437388 DOI: 10.1097/tp.0000000000001704] [Cited by in Crossref: 36] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
298 Martin MT, Koppe S. Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis. Transplantation 2017;101:2088-91. [PMID: 28376038 DOI: 10.1097/TP.0000000000001758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
299 Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012;2012:686135. [PMID: 22900194 DOI: 10.1155/2012/686135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
300 Salizzoni M, Cerutti E, Romagnoli R, Lupo F, Franchello A, Zamboni F, Gennari F, Strignano P, Ricchiuti A, Brunati A, Schellino MM, Ottobrelli A, Marzano A, Lavezzo B, David E, Rizzetto M. The first one thousand liver transplants in Turin: a single-center experience in Italy. Transpl Int 2005;18:1328-35. [PMID: 16297051 DOI: 10.1111/j.1432-2277.2005.00215.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
301 Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, Boillot O. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant. 2007;7:177-184. [PMID: 17227566 DOI: 10.1111/j.1600-6143.2006.01590.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
302 Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36-S44. [PMID: 18825724 DOI: 10.1002/lt.21646] [Cited by in Crossref: 203] [Cited by in F6Publishing: 172] [Article Influence: 15.6] [Reference Citation Analysis]
303 Bellido-Muñoz F, Giráldez-Gallego A, Roca-Oporto C, García-Cayuela T, Pascasio-Acevedo JM, Sousa-Martín JM. Monitoring the natural evolution and response to treatment of post liver transplant recurrent hepatitis C using transient elastography: preliminary results. Transplant Proc 2012;44:2082-6. [PMID: 22974917 DOI: 10.1016/j.transproceed.2012.07.090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
304 Fox AN, Brown RS. Is the Patient a Candidate for Liver Transplantation? Clinics in Liver Disease 2012;16:435-48. [DOI: 10.1016/j.cld.2012.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
305 Vasavada B. Prior Trans-arterial chemoembolization - A protective factor against rapid HCV recurrence post liver transplant in patients with HCV with HCC? - A Retrospective Cohort Study. Int J Surg 2016;30:132-5. [PMID: 27154618 DOI: 10.1016/j.ijsu.2016.04.050] [Reference Citation Analysis]
306 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 7.4] [Reference Citation Analysis]
307 Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol. 2014;11:710-721. [PMID: 25023032 DOI: 10.1038/nrgastro.2014.114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
308 Shackel NA, Jamias J, Rahman W, Prakoso E, Strasser SI, Koorey DJ, Crawford MD, Verran DJ, Gallagher J, McCaughan GW. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl. 2009;15:709-718. [PMID: 19562704 DOI: 10.1002/lt.21747] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
309 Canivet C, Böhler T, Galvani S, Péron J, Muscari F, Alric L, Barange K, Salvayre R, Negre-salvayre A, Durand D, Suc B, Izopet J, Thomsen M, Rostaing L, Kamar N. In vitro mitogen-stimulated T-cell from hepatitis C virus-positive liver transplantation candidates, increases T-cell activation markers and T-cell proliferation. Transplant Immunology 2008;19:112-9. [DOI: 10.1016/j.trim.2008.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
310 Dove LM. Management of hepatitis C after transplantation: a long way from success. European Journal of Gastroenterology & Hepatology 2004;16:1131-3. [DOI: 10.1097/00042737-200411000-00008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
311 Scherzer TM, Staufer K, Novacek G, Steindl-Munda P, Schumacher S, Hofer H, Ferenci P, Vogelsang H. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008;28:742-748. [PMID: 19145730 DOI: 10.1111/j.1365-2036.2008.03779.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
312 Weinrieb RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl. 2004;10:97-106. [PMID: 14755785 DOI: 10.1002/lt.20003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
313 Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-kabany M, Han S, Busuttil RW. Boceprevir in liver transplant recipients. Liver Int 2015;35:192-7. [DOI: 10.1111/liv.12548] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
314 Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int. 2010;23:580-588. [PMID: 20028490 DOI: 10.1111/j.1432-2277.2009.01023.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
315 Klein F, Neuhaus R, Eurich D, Hofmann J, Bayraktar S, Pratschke J, Bahra M. Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepat Res Treat 2016;2016:8325467. [PMID: 27195149 DOI: 10.1155/2016/8325467] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
316 Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640 [PMID: 33033569 DOI: 10.4254/wjh.v12.i9.628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
317 Lin TY, Yeh ML, Huang CI, Chen YL, Dai CY, Huang JF, Lin ZY, Chen SC, Huang CF, Yu ML, Chuang WL. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. Kaohsiung J Med Sci 2017;33:284-9. [PMID: 28601232 DOI: 10.1016/j.kjms.2017.03.007] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
318 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
319 Rubín A, Berenguer M. [Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma]. Gastroenterol Hepatol 2013;36:48-57. [PMID: 22578313 DOI: 10.1016/j.gastrohep.2012.03.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
320 Viral hepatitis guidelines in hemodialysis and transplantation Am J Transplant. 2004;4 Suppl 10:72-82. [PMID: 15504218 DOI: 10.1111/j.1600-6135.2004.00676.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
321 Pollard S. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Int 2004;24:402-6. [DOI: 10.1111/j.1478-3231.2004.0987.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
322 Holt CD, Winston DJ. Infections After Liver Transplantation. Transplantation of the Liver. Elsevier; 2005. pp. 963-94. [DOI: 10.1016/b978-0-7216-0118-2.50069-0] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
323 Bárcena R, Moreno A, Rodríguez-Gandía MA, Albillos A, Arocena C, Blesa C, García-Hoz F, Graus J, Nuño J, López-Hervás P, Gajate L, Martínez A, Bermejo T, Mateos ML, Del Campo S; Hospital Ramón y Cajal Liver Transplant Group. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013;58:421-6. [PMID: 23073223 DOI: 10.1016/j.jhep.2012.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
324 Mukherjee S, Rogge J, Weaver L, Schafer D. De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation. Transplantation Proceedings 2004;36:1494-7. [DOI: 10.1016/j.transproceed.2004.05.058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
325 Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, Stiegler P, Tscheliessnigg KH, Iberer F. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol. 2010;10:990-993. [PMID: 20483386 DOI: 10.1016/j.intimp.2010.05.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
326 Alqahtani SA, Larson AM. Adult liver transplantation in the USA: . Current Opinion in Gastroenterology 2011;27:240-7. [DOI: 10.1097/mog.0b013e3283457d5d] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
327 Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant. 2006;6:1398-1406. [PMID: 16686763 DOI: 10.1111/j.1600-6143.2006.01256.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
328 Khalili M, Vardanian AJ, Hamerski CM, Wang R, Bacchetti P, Roberts JP, Terrault NA. Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant 2006;20:1-9. [DOI: 10.1111/j.1399-0012.2005.00449.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
329 McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-S13. [PMID: 12362292 DOI: 10.1053/jlts.2002.35856] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
330 Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transpl 2006;12:1594-606. [DOI: 10.1002/lt.20764] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 6.0] [Reference Citation Analysis]
331 Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8:S14-8. [PMID: 12362293 DOI: 10.1053/jlts.2002.35781] [Cited by in Crossref: 198] [Cited by in F6Publishing: 183] [Article Influence: 9.9] [Reference Citation Analysis]
332 Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis. 2006;8:3-12. [PMID: 16623815 DOI: 10.1111/j.1399-3062.2006.00124.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
333 Carrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol. 2010;53:962-970. [PMID: 20800307 DOI: 10.1016/j.jhep.2010.06.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
334 Berenguer M, Charco R, Manuel Pascasio J, Ignacio Herrero J. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int. 2012;32:712-731. [PMID: 22221843 DOI: 10.1111/j.1478-3231.2011.02731.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
335 Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005;11:941-949. [PMID: 16035063 DOI: 10.1002/lt.20405] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 7.8] [Reference Citation Analysis]
336 Buganza-torio E, Doucette KE. Management of Viral Hepatitis in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America 2018;32:635-50. [DOI: 10.1016/j.idc.2018.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
337 Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol. 2009;24:574-580. [PMID: 19368635 DOI: 10.1111/j.1440-1746.2008.05638.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
338 Tretheway D, Jain A, Lapoint R, Sharma R, Orloff M, Milot P, Bozorgzadeh A, Ryan C. Should trichrome stain be used on all post–liver transplant biopsies with hepatitis c virus infection to estimate the fibrosis score? Liver Transpl 2008;14:695-700. [DOI: 10.1002/lt.21422] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
339 Smallwood GA, Devine R, Fasola C, Stieber AC, Heffron TG. Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation? Transplantation 2008;86:1795-8. [PMID: 19104424 DOI: 10.1097/TP.0b013e3181914188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
340 Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, Mchutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology 2015;148:108-17. [DOI: 10.1053/j.gastro.2014.10.001] [Cited by in Crossref: 274] [Cited by in F6Publishing: 240] [Article Influence: 39.1] [Reference Citation Analysis]
341 Skoglund C, Lagging M, Castedal M. No need to discontinue hepatitis C virus therapy at the time of liver transplantation. PLoS One 2019;14:e0211437. [PMID: 30794555 DOI: 10.1371/journal.pone.0211437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
342 Khalid SK, Crippin JS. Management of Hepatitis C in the Setting of Liver Transplantation. Clinics in Liver Disease 2006;10:321-37. [DOI: 10.1016/j.cld.2006.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
343 Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3-26. [PMID: 23281277 DOI: 10.1002/lt.23566] [Cited by in Crossref: 276] [Cited by in F6Publishing: 205] [Article Influence: 30.7] [Reference Citation Analysis]
344 Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, Reddy R, Markmann JF. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation. 2004;77:1834-1842. [PMID: 15223900 DOI: 10.1097/01.tp.0000130468.36131.0d] [Cited by in Crossref: 78] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
345 Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation. 2007;84:331-339. [PMID: 17700157 DOI: 10.1097/01.tp.0000270313.31328.63] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
346 Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis 2016;16:735-45. [PMID: 27301929 DOI: 10.1016/S1473-3099(16)00120-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
347 Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H, Chayama K. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. Clin J Gastroenterol 2017;10:179-84. [PMID: 28224470 DOI: 10.1007/s12328-017-0722-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
348 Garcia-retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707. [DOI: 10.1002/hep.20357] [Cited by in Crossref: 157] [Cited by in F6Publishing: 129] [Article Influence: 8.7] [Reference Citation Analysis]
349 de la Peña-moral JM, Pons JA, Tome S, Gude F, Miras M, Bermejo J, Ramirez P, Berenguer M, Varo E, Forteza J, Parrilla P. Acute cellular rejection versus recurrent hepatitis C after liver transplantation: Clinical and pathological features driving a rational diagnostic approach: Acute rejection vs recurrent HCV after LT. Hepatol Res 2015;45:423-31. [DOI: 10.1111/hepr.12369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
350 Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32:2117-2138. [PMID: 21316532 DOI: 10.1016/s0149-2918(11)00022-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
351 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
353 Agarwal PD, Lucey MR. Sirolimus: More cause for alarm? Liver Transpl 2012;18:1003-4. [DOI: 10.1002/lt.23473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
354 Rezaee-zavareh MS, Hesamizadeh K, Sharafi H, Alavian SM. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
355 Olivera-Martínez MA, Gallegos-Orozco JF. Recurrent viral liver disease (hepatitis B and C) after liver transplantation. Arch Med Res 2007;38:691-701. [PMID: 17613360 DOI: 10.1016/j.arcmed.2006.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
356 Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009;50:719-728. [PMID: 19217183 DOI: 10.1016/j.jhep.2008.11.015] [Cited by in Crossref: 151] [Cited by in F6Publishing: 127] [Article Influence: 10.8] [Reference Citation Analysis]
357 Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258-1262. [PMID: 15376310 DOI: 10.1002/lt.20222] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 6.3] [Reference Citation Analysis]
358 Asaoka T, Marubashi S, Kobayashi S, Hama N, Eguchi H, Takeda Y, Tanemura M, Wada H, Takemasa I, Takahashi H, Ruiz P, Doki Y, Mori M, Nagano H. Intragraft transcriptome level of CXCL9 as biomarker of acute cellular rejection after liver transplantation. J Surg Res 2012;178:1003-14. [PMID: 22889476 DOI: 10.1016/j.jss.2012.07.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
359 Crespo S, Bridges M, Nakhleh R, McPhail A, Pungpapong S, Keaveny AP. Non-invasive assessment of liver fibrosis using magnetic resonance elastography in liver transplant recipients with hepatitis C. Clin Transplant 2013;27:652-8. [PMID: 23837611 DOI: 10.1111/ctr.12180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
360 Charlton M. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transplantation 2002;8:S50-4. [DOI: 10.1053/jlts.2002.35859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
361 Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl. 2003;9:796-804. [PMID: 12884191 DOI: 10.1053/jlts.2003.50164] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
362 Teixeira R, Godinho Menezes É, Schiano TD. Therapeutic management of recurrent hepatitis C after liver transplantation. Liver Int 2007;27:302-12. [DOI: 10.1111/j.1478-3231.2006.01426.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
363 Trotter JF, Osborne JC, Heller M, Christians U. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. Aliment Pharmacol Ther 2005;22:37-44. [PMID: 15963078 DOI: 10.1111/j.1365-2036.2005.02502.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
364 Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, Dametto E, Rizzetto M, Salizzoni M, Amoroso A. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016;29:1070-84. [DOI: 10.1111/tri.12795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
365 Rodriguez-luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-89. [DOI: 10.1002/lt.20424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
366 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
367 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
368 Marshall A, Rushbrook S, Morris LS, Scott IS, Vowler SL, Davies SE, Coleman N, Alexander G. Hepatocyte expression of minichromosome maintenance protein-2 predicts fibrosis progression after transplantation for chronic hepatitis C virus: a pilot study. Liver Transpl 2005;11:427-33. [PMID: 15776414 DOI: 10.1002/lt.20347] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
369 McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl. 2003;9:S21-S27. [PMID: 14586891 DOI: 10.1053/jlts.2003.50269] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
370 Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. Hepatol Res 2016;46:707-12. [PMID: 26439054 DOI: 10.1111/hepr.12602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
371 Beinhardt S, Peck-Radosavljevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transpl Int. 2015;28:1011-1024. [PMID: 25864369 DOI: 10.1111/tri.12577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
372 Zhang D, Guo Z, Zhang P, Li Y, Su X, You L, Gao M, Liu C, Wu H, Zhang X. Simplified quantification method for in vivo SPECT/CT imaging of asialoglycoprotein receptor with (99m)Tc-p(VLA-co-VNI) to assess and stage hepatic fibrosis in mice. Sci Rep. 2016;6:25377. [PMID: 27150943 DOI: 10.1038/srep25377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
373 Mawardi M, Aba Alkhail F, Katada K, Levstik M, Quan D, Wall W, Marotta P, Hernandezalejandro R. The clinical consequences of utilizing donation after cardiac death liver grafts into hepatitis C recipients. Hepatol Int 2011;5:830-3. [DOI: 10.1007/s12072-010-9242-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
374 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am 2006;20:1-25. [PMID: 16527646 DOI: 10.1016/j.idc.2006.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
375 Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol 2016;1:165-72. [PMID: 28404073 DOI: 10.1016/S2468-1253(16)30008-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
376 Habib S, Meister E, Habib S, Murakami T, Walker C, Rana A, Shaikh OS. Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res. 2015;8:237-246. [PMID: 27785303 DOI: 10.14740/gr686w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
377 Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007;13:1100-1108. [PMID: 17377914 DOI: 10.1002/lt.21121] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
378 Kamo N, Kaido T, Hammad A, Ogawa K, Fujimoto Y, Uemura T, Mori A, Hatano E, Okajima H, Uemoto S. Impact of elderly donors for liver transplantation: A single-center experience. Liver Transpl. 2015;21:591-598. [PMID: 25641778 DOI: 10.1002/lt.24086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
379 Habib S, Malik S, Fu B, Chang J, Nalesnik M, Humar A, Shaikh OS. Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy. Gastroenterology Res 2015;8:281-90. [PMID: 27785310 DOI: 10.14740/gr694w] [Reference Citation Analysis]
380 Biggins SW, Terrault NA. Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis. 2005;9:505-523, ix. [PMID: 16023980 DOI: 10.1016/j.cld.2005.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
381 Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015;28:980-989. [PMID: 25818896 DOI: 10.1111/tri.12568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
382 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
383 Roche B, Samuel D. Are viral or host factors predictive of response to interferon–ribavirin in transplant patients with hepatitis C? Journal of Hepatology 2010;52:630-2. [DOI: 10.1016/j.jhep.2010.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
384 Saab S, Challita Y, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo FA, El-Kabany MM, Han SB, Grotts J, Agopian VG, Busuttil RW. Elimination of Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol 2018;6:247-50. [PMID: 30271735 DOI: 10.14218/JCTH.2017.00079] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
385 Michta ML, Hopcraft SE, Narbus CM, Kratovac Z, Israelow B, Sourisseau M, Evans MJ. Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol 2010;84:11696-708. [PMID: 20844048 DOI: 10.1128/JVI.01555-10] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
386 Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14:994-1002. [PMID: 24730431 DOI: 10.1111/ajt.12714] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 8.6] [Reference Citation Analysis]
387 Golden-Mason L. Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation. Liver Transpl. 2009;15:357-359. [PMID: 19326413 DOI: 10.1002/lt.21701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
388 Heil EL, Hynicka LM, Kottilil S, Tang L. What does the pharmacological future of treating chronic hepatitis C look like? Expert Rev Clin Pharmacol 2015;8:605-22. [PMID: 26289223 DOI: 10.1586/17512433.2015.1074859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
389 Boin IF, Ataide EC, Leonardi MI, Stucchi R, Sevá-Pereira T, Pereira IW, Cardoso AR, Caruy CA, Luzo A, Leonardi LS. Elderly donors for HCV(+) versus non-HCV recipients: patient survival following liver transplantation. Transplant Proc. 2008;40:792-796. [PMID: 18455019 DOI: 10.1016/j.transproceed.2008.02.069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
390 Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl. 2015;21:423-434. [PMID: 25604355 DOI: 10.1002/lt.24080] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
391 Castells L, Escartín A, Bilbao I, Len O, Allende H, Vargas V, Ribera E, Lázaro JL, Bueno J, Balsells J. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation. 2007;83:354-358. [PMID: 17297413 DOI: 10.1097/01.tp.0000251378.70853.90] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
392 Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007;20:583-590. [PMID: 17433090 DOI: 10.1111/j.1432-2277.2007.00481.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
393 Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88:1351-1389. [PMID: 24792322 DOI: 10.1111/j.1432-2277.2011.01250.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
394 . EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology 2014;61:373-95. [DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 16.0] [Reference Citation Analysis]
395 Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68. [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012] [Cited by in Crossref: 449] [Cited by in F6Publishing: 417] [Article Influence: 56.1] [Reference Citation Analysis]
396 Lauer GM. Hepatitis C virus–specific CD8 + T cells restricted by donor HLA alleles following liver transplantation. Liver Transpl 2005;11:848-50. [DOI: 10.1002/lt.20423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
397 Bunchorntavakul C, Tanwandee T. Treatment of Chronic Hepatitis C in Special Populations. Gastroenterology Clinics of North America 2015;44:883-900. [DOI: 10.1016/j.gtc.2015.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
398 Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review. Saudi J Gastroenterol 2013;19:223-9. [PMID: 24045596 DOI: 10.4103/1319-3767.118133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
399 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
400 Arjal RR, Burton Jr JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Alimentary Pharmacology & Therapeutics 2007;26:127-40. [DOI: 10.1111/j.1365-2036.2007.03364.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
401 Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. J Hepatol. 2012;57:564-571. [PMID: 22613001 DOI: 10.1016/j.jhep.2012.04.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
402 Brown KA. From Heresy to Standard of Care: A Virologic Journey. Liver Transpl 2021;27:486-8. [PMID: 33460506 DOI: 10.1002/lt.25983] [Reference Citation Analysis]
403 Asselah T, Boudjema H, Francoz C, Sobesky R, Valla D, Belghiti J, Marcellin P, Durand F. Hépatite C et transplantation hépatique. Gastroentérologie Clinique et Biologique 2006;30:1281-95. [DOI: 10.1016/s0399-8320(06)73536-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
404 Prakoso E, Tirnitz-parker JEE, Clouston AD, Kayali Z, Lee A, Gan EK, Ramm GA, Kench JG, Bowen DG, Olynyk JK, Mccaughan GW, Shackel NA. Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation: DUCTULAR REACTION IN RECURRENT HCV AFTER TRANSPLANTATION. Liver Transpl 2014;20:1508-19. [DOI: 10.1002/lt.24007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
405 Walter T, Scoazec JY, Guillaud O, Hervieu V, Chevallier P, Boillot O, Dumortier J. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl. 2009;15:54-63. [PMID: 19109834 DOI: 10.1002/lt.21652] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
406 Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat. 2006;13:538-543. [PMID: 16901284 DOI: 10.1111/j.1365-2893.2006.00720.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
407 Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int. 2013;26:358-372. [PMID: 23413991 DOI: 10.1111/tri.12065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
408 Bárcena R, Moreno A, Foruny JR, Moreno A, Sánchez J, Gil-Grande L, Blázquez J, Nuño J, Fortún J, Rodriguez-Gandía MA, Otón E. Improved graft function in liver-transplanted patients after partial splenic embolization: reversal of splenic artery steal syndrome? Clin Transplant 2006;20:517-23. [PMID: 16842531 DOI: 10.1111/j.1399-0012.2006.00516.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
409 Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol. 2013;2013:890517. [PMID: 23710205 DOI: 10.1155/2013/890517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
410 Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res. 2013;43:1-34. [PMID: 23332085 DOI: 10.1111/hepr.12020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
411 Burton JR, Rosen HR. Diagnosis and Management of Allograft Failure. Clinics in Liver Disease 2006;10:407-35. [DOI: 10.1016/j.cld.2006.05.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
412 Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst Rev. 2013;12:CD006803. [PMID: 24307460 DOI: 10.1002/14651858.cd006803.pub4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
413 Wieczorek-Godlewska R, Płoski R, Perkowska-Ptasińska A, Tronina O, Sadowska A, Pacholczyk M, Lisik W, Durlik M. The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation. Clin Exp Hepatol 2017;3:152-8. [PMID: 29062905 DOI: 10.5114/ceh.2017.68401] [Reference Citation Analysis]
414 Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl. 2003;9:S44-S47. [PMID: 14586894 DOI: 10.1053/jlts.2003.50243] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
415 Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12:51-57. [PMID: 16382464 DOI: 10.1002/lt.20532] [Cited by in Crossref: 128] [Cited by in F6Publishing: 109] [Article Influence: 8.0] [Reference Citation Analysis]
416 Gane E. Renal transplantation in chronic hepatitis C. J Gastroenterol Hepatol 2004;19:S99-S102. [DOI: 10.1111/j.1440-1746.2004.03653.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
417 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
418 Fasola CG, Klintmalm GB. Hepatitis C recurrence after liver transplantation: in search of the optimal immunosuppression to improve outcome. Current Opinion in Organ Transplantation 2006;11:637-42. [DOI: 10.1097/mot.0b013e328010d4c1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
419 Joshi D, Carey I, Foxton M, Al-freah M, Bruce M, Heaton N, Quaglia A, O'grady J, Aluvihare V, Agarwal K. CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response. Clin Transplant 2014;28:569-78. [DOI: 10.1111/ctr.12354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
420 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
421 Fink S, Gaglio PJ. Hepatitis C in liver transplant patients. Curr hepatitis rep 2008;7:81-7. [DOI: 10.1007/s11901-008-0012-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
422 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Cescon M, Varotti G, Ramacciato G, Vetrone G, Zanello M, Pinna AD. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. Liver Transpl 2006;12:1104-11. [DOI: 10.1002/lt.20725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
423 Kardashian AA, Price JC. Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant 2015;20:276-85. [PMID: 25944240 DOI: 10.1097/MOT.0000000000000199] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
424 Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 2006;12:1317-9. [PMID: 16933225 DOI: 10.1002/lt.20889] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
425 Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis. 2003;7:107-125. [PMID: 12691461 DOI: 10.1016/s1089-3261(02)00073-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
426 Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, Alonzo J, Garcia-Kennedy R, Rayón JM, Wright TL. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 2003;38:34-41. [PMID: 12829984 DOI: 10.1053/jhep.2003.50278] [Cited by in Crossref: 175] [Cited by in F6Publishing: 157] [Article Influence: 9.2] [Reference Citation Analysis]
427 Cholankeril G, Joseph-Talreja M, Perumpail BJ, Liu A, Yoo ER, Ahmed A, Goel A. Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. J Clin Transl Hepatol 2017;5:363-7. [PMID: 29226102 DOI: 10.14218/JCTH.2017.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
428 Gallegos-orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. Journal of Hepatology 2004;41:512-21. [DOI: 10.1016/j.jhep.2004.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
429 Schirren CA, Zachoval R, Gerlach JT, Ulsenheimer A, Gruener NH, Diepolder HM, Baretton G, Schraut W, Rau H, Nitschko H, Pape GR, Jung M. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. Journal of Hepatology 2003;39:397-404. [DOI: 10.1016/s0168-8278(03)00266-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
430 Testillano M, Fernandez J, Suarez M, Gastaca M, Bustamante J, Pijoan J, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J. Survival and Hepatitis C Virus Recurrence After Liver Transplantation in HIV- and Hepatitis C Virus–Coinfected Patients: Experience in a Single Center. Transplantation Proceedings 2009;41:1041-3. [DOI: 10.1016/j.transproceed.2009.02.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
431 Wu Y, Ahmed A, Kamal A. Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients. Dig Dis Sci. 2013;58:574-578. [PMID: 22923335 DOI: 10.1007/s10620-012-2345-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
432 Morard I, Negro F. How should we treat recurrent hepatitis C after liver transplantation? Journal of Hepatology 2005;42:462-8. [DOI: 10.1016/j.jhep.2005.01.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
433 Pyrsopoulos N, Jeffers L. Chronic hepatitis C in African Americans. Clin Liver Dis 2005;9:427-38, vii. [PMID: 16023975 DOI: 10.1016/j.cld.2005.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
434 Mensa L, Pérez-del-Pulgar S, Crespo G, Koutsoudakis G, Fernández-Carrillo C, Coto-Llerena M, Miquel R, Allende H, Castells L, Navasa M. Imaging of hepatitis C virus infection in liver grafts after liver transplantation. J Hepatol. 2013;59:271-278. [PMID: 23548198 DOI: 10.1016/j.jhep.2013.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
435 Bozzano F, Marras F, Biassoni R, De Maria A. Natural killer cells in hepatitis C virus infection. Expert Rev Clin Immunol 2012;8:775-88. [PMID: 23167689 DOI: 10.1586/eci.12.71] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
436 Gwak GY. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis]. Korean J Gastroenterol 2016;67:137-41. [PMID: 26996183 DOI: 10.4166/kjg.2016.67.3.137] [Reference Citation Analysis]
437 Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat. 2007;14 Suppl 1:89-96. [PMID: 17958649 DOI: 10.1111/j.1365-2893.2007.00920.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
438 Burra P, Zanetto A. Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. Transpl Int 2017;30:239-42. [PMID: 28102906 DOI: 10.1111/tri.12917] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, Girgrah N, Herath C, Levy GA, Lilly L. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214-1221. [PMID: 19935376 DOI: 10.1097/tp.0b013e3181bd783c] [Cited by in Crossref: 103] [Cited by in F6Publishing: 20] [Article Influence: 8.6] [Reference Citation Analysis]
440 Gurusamy KS, Osmani B, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2009;:CD006803. [PMID: 19160303 DOI: 10.1002/14651858.CD006803.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
441 Sugawara Y, Makuuchi M. Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol 2006; 12(28): 4461-4465 [PMID: 16874855 DOI: 10.3748/wjg.v12.i28.4461] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
442 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
443 Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016;22:446-58. [PMID: 26890629 DOI: 10.1002/lt.24416] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 10.3] [Reference Citation Analysis]
444 Nagler E, Van Vlierberghe H, Colle I, Troisi R, de Hemptinne B. Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective. Eur J Gastroenterol Hepatol 2005;17:849-56. [PMID: 16003135 DOI: 10.1097/00042737-200508000-00012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
445 Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, Patch D, Burroughs A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15:699-709. [PMID: 18673428 DOI: 10.1111/j.1365-2893.2008.01019.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 6.2] [Reference Citation Analysis]
446 Saab S, Wang V. Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. J Clin Gastroenterol 2003;37:155-63. [PMID: 12869888 DOI: 10.1097/00004836-200308000-00013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
447 Cuervas-Mons V, de la Rosa G, Pardo F, San Juan F, Valdivieso A. [Activity and results of liver transplantation in Spain during 1984-2012. Analysis of the Spanish Liver Transplant Registry]. Med Clin (Barc). 2015;144:337-347. [PMID: 25458515 DOI: 10.1016/j.medcli.2014.07.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
448 Berenguer M. Outcome of posttransplantation hepatitis C virus disease[mdash ]Is it the host, the virus, or how we modify the host and/or the virus? Liver Transplantation;8:889-91. [DOI: 10.1053/jlts.2002.35841] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
449 Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012;32:120-8. [DOI: 10.1111/j.1478-3231.2011.02714.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
450 Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601-1605. [PMID: 23593993 DOI: 10.1111/ajt.12209] [Cited by in Crossref: 110] [Cited by in F6Publishing: 99] [Article Influence: 12.2] [Reference Citation Analysis]
451 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America 2005;89:345-69. [DOI: 10.1016/j.mcna.2004.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
452 Toniutto P, Fabris C, Falleti E, Cussigh A, Fontanini E, Bitetto D, Fornasiere E, Minisini R, De Feo T, Marangoni F, Pirisi M. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C: MTHFR genotypes and recurrent hepatitis C. Liver International 2008;28:257-63. [DOI: 10.1111/j.1478-3231.2007.01591.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
453 Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132-1139.e1. [PMID: 22285805 DOI: 10.1053/j.gastro.2012.01.030] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
454 El-yazbi AF, Khalifa Y, Elkhatib MA, El-yazbi AF. Green analytical method for the determination of sofosbuvir, ledipasvir, ribavirin and complex silymarin flavonoids simultaneously in biological fluids. Microchemical Journal 2021;164:105964. [DOI: 10.1016/j.microc.2021.105964] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
455 Biggins SW. How effective are 3-month and 12-month predictive models of mortality after first liver transplantation? Nat Rev Gastroenterol Hepatol 2006;3:430-1. [DOI: 10.1038/ncpgasthep0554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
456 Roche B, Samuel D. Hepatitis C virus: Up to the minute. Liver Transpl 2010;16:S26-35. [DOI: 10.1002/lt.22154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
457 Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:78-86. [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018] [Cited by in Crossref: 157] [Cited by in F6Publishing: 133] [Article Influence: 17.4] [Reference Citation Analysis]
458 Charlton M. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 2007;9:23-30. [DOI: 10.1007/s11894-008-0017-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
459 Cano A, Mariño Z, Millet O, Martínez-Arranz I, Navasa M, Falcón-Pérez JM, Pérez-Cormenzana M, Caballería J, Embade N, Forns X, Bosch J, Castro A, Mato JM. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Sci Rep 2017;7:10497. [PMID: 28874799 DOI: 10.1038/s41598-017-10807-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
460 van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl 2006;12:448-56. [PMID: 16498656 DOI: 10.1002/lt.20702] [Cited by in Crossref: 98] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
461 Maheshwari E, Tublin ME. Sonography of liver transplantation. Abdom Radiol (NY) 2021;46:68-83. [PMID: 33043396 DOI: 10.1007/s00261-020-02799-7] [Reference Citation Analysis]
462 Rakela J. Hepatitis C: Magnitude of the problem. Liver Transplantation 2002;8:S3-6. [DOI: 10.1053/jlts.2002.35855] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
463 Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43:1101-1108. [PMID: 16628706 DOI: 10.1002/hep.21164] [Cited by in Crossref: 217] [Cited by in F6Publishing: 200] [Article Influence: 13.6] [Reference Citation Analysis]
464 Crespo G, Mariño Z, Navasa M, Forns X. Viral Hepatitis in Liver Transplantation. Gastroenterology 2012;142:1373-1383.e1. [DOI: 10.1053/j.gastro.2012.02.011] [Cited by in Crossref: 149] [Cited by in F6Publishing: 128] [Article Influence: 14.9] [Reference Citation Analysis]
465 Punzalan CS, Barry C, Zacharias I, Rodrigues J, Mehta S, Bozorgzadeh A, Barnard GF. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015;29:1105-1111. [PMID: 26358816 DOI: 10.1111/ctr.12634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
466 Ueda Y, Marusawa H, Kaido T, Ogura Y, Oike F, Mori A, Ogawa K, Yoshizawa A, Hatano E, Miyagawa-hayashino A, Haga H, Egawa H, Takada Y, Uemoto S, Chiba T. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation: Maintenance therapy for HCV after LDLT. Journal of Viral Hepatitis 2012;19:32-8. [DOI: 10.1111/j.1365-2893.2010.01398.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
467 Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wängberg B, Ahlman H. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007;13:327-33. [PMID: 17318853 DOI: 10.1002/lt.21056] [Cited by in Crossref: 96] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
468 Berenguer M, Agarwal K, Burra P, Manns M, Samuel D. The road map toward an hepatitis C virus-free transplant population. Am J Transplant 2018;18:2409-16. [PMID: 29935050 DOI: 10.1111/ajt.14976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
469 Karam V, Sebagh M, Rifai K, Yilmaz F, Bhangui P, Danet C, Saliba F, Samuel D, Castaing D, Adam R, Feray C. Quality of life 10 years after liver transplantation: The impact of graft histology. World J Transplant 2016; 6(4): 703-711 [PMID: 28058221 DOI: 10.5500/wjt.v6.i4.703] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
470 Halliday N, Westbrook RH. Liver transplantation: post-transplant management. British Journal of Hospital Medicine 2017;78:278-85. [DOI: 10.12968/hmed.2017.78.5.278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
471 Taylor J, Cox-North P, Landis CS. Management of Post-Liver Transplant Recurrence of Hepatitis C. Drugs 2016;76:1711-7. [PMID: 27878476 DOI: 10.1007/s40265-016-0658-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
472 Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl. 2004;10:886-897. [PMID: 15237373 DOI: 10.1002/lt.20137] [Cited by in Crossref: 262] [Cited by in F6Publishing: 221] [Article Influence: 15.4] [Reference Citation Analysis]
473 Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat. 2013;20:770-778. [PMID: 24168256 DOI: 10.1111/jvh.12099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
474 Berenguer M. Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence: . Current Opinion in Organ Transplantation 2006;11:599-607. [DOI: 10.1097/mot.0b013e3280106c3d] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
475 Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzabosco M, Tisone G. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007;46:1009-1017. [PMID: 17328985 DOI: 10.1016/j.jhep.2006.12.017] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
476 Masuzaki R, Yamashiki N, Sugawara Y, Yoshida H, Tateishi R, Tamura S, Kaneko J, Hasegawa K, Kokudo N, Makuuchi M, Omata M. Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Scand J Gastroenterol 2009;44:1115-20. [PMID: 19562623 DOI: 10.1080/00365520903078810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
477 Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. Hepatology 2005;41:436-8. [DOI: 10.1002/hep.20623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
478 Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int. 2005;18:1336-1345. [PMID: 16297052 DOI: 10.1111/j.1432-2277.2005.00217.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
479 Porrett PM, Hashmi SK, Shaked A. Immunosuppression: trends and tolerance? Clin Liver Dis 2014;18:687-716. [PMID: 25017084 DOI: 10.1016/j.cld.2014.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
480 Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. Hepatol Res. 2011;41:1126-1131. [PMID: 22032680 DOI: 10.1111/j.1872-034x.2011.00853.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
481 Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, Descalzi V, Villamil F. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl 2011;17:824-35. [PMID: 21618696 DOI: 10.1002/lt.22309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
482 Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, Nair S, Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol 2018; 24(3): 315-322 [PMID: 29391754 DOI: 10.3748/wjg.v24.i3.315] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
483 Bahr M, Manns M. Recurrent hepatitis C in transplanted patients: more questions than answers. Digestive and Liver Disease 2003;35:2-6. [DOI: 10.1016/s1590-8658(02)00003-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
484 Shoreibah M, Romano J, Sims OT, Guo Y, Jones D, Venkata K, Kommineni V, Orr J, Fitzmorris P, Massoud OI. Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients. J Clin Transl Hepatol 2018;6:391-5. [PMID: 30637216 DOI: 10.14218/JCTH.2018.00026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
485 Bahr MJ, Manns MP. Changing faces-natural course and treatment of hepatitis C after liver transplantation. J Hepatol. 2004;40:699-701. [PMID: 15030989 DOI: 10.1016/j.jhep.2004.01.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
486 Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol. 2006;36:283-291. [PMID: 16765638 DOI: 10.1016/j.jcv.2006.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
487 Novelli G, Rossi M, Morabito V, Ferretti G, Pretagostini R, Ruberto F, Pugliese F, Guglielmo N, Berloco P. Management of Hepatitis C Virus Infection in Liver Transplantation with Adacolumn Apheresis. Transplantation Proceedings 2012;44:1946-52. [DOI: 10.1016/j.transproceed.2012.06.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
488 Petrowsky H, Rana A, Kaldas FM, Sharma A, Hong JC, Agopian VG, Durazo F, Honda H, Gornbein J, Wu V. Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg. 2014;259:1186-1194. [PMID: 24263317 DOI: 10.1097/sla.0000000000000265] [Cited by in Crossref: 113] [Cited by in F6Publishing: 30] [Article Influence: 14.1] [Reference Citation Analysis]
489 Sanyal R, Lall CG, Lamba R, Verma S, Shah SN, Tirkes T, Berry WA, Sandrasegaran K. Orthotopic liver transplantation: reversible Doppler US findings in the immediate postoperative period. Radiographics. 2012;32:199-211. [PMID: 22236901 DOI: 10.1148/rg.321115006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
490 Moeller M, Zalawadia A, Alrayes A, Divine G, Brown K, Moonka D. The Impact of Donor Race on Recurrent Hepatitis C after Liver Transplantation. Transplantation Proceedings 2010;42:4175-7. [DOI: 10.1016/j.transproceed.2010.09.079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
491 Kwo PY, Lacerda MA. After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver. Gastroenterology 2016;151:582-4. [PMID: 27590790 DOI: 10.1053/j.gastro.2016.08.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
492 Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol 2015;15:98. [PMID: 26239358 DOI: 10.1186/s12876-015-0320-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
493 Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. Expert Review of Gastroenterology & Hepatology 2014;4:445-58. [DOI: 10.1586/egh.10.39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
494 Dhanasekaran R, Firpi RJ. Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol 2014; 20(13): 3391-3400 [PMID: 24707122 DOI: 10.3748/wjg.v20.i13.3391] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
495 Ackefors M, Castedal M, Dahlgard O, Verbaan H, Gjertsen H, Wernerson A, Weiland O. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. Infect Dis (Lond) 2015;47:209-17. [PMID: 25650729 DOI: 10.3109/00365548.2014.984322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
496 Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, McAlister V, Levstik MA, Wall W, Marotta P. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation. 2011;92:686-689. [PMID: 21832962 DOI: 10.1097/tp.0b013e31822a79d2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
497 Alkhouri N, Hanouneh IA, Lopez R, Zein NN. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression. Liver Transpl. 2010;16:155-162. [PMID: 20104483 DOI: 10.1002/lt.21939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
498 Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006;12:1805-12. [PMID: 17133585 DOI: 10.1002/lt.20883] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
499 Yedibela S, Schuppan D, Müller V, Schellerer V, Tannapfel A, Hohenberger W, Meyer T. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int. 2005;25:717-722. [PMID: 15998420 DOI: 10.1111/j.1478-3231.2005.1065.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
500 Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation. 2010;90:661-665. [PMID: 20110853 DOI: 10.1097/tp.0b013e3181d2bfca] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
501 Bunchorntavakul C, Reddy KR. Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J Clin Transl Hepatol 2014;2:124-33. [PMID: 26357623 DOI: 10.14218/JCTH.2014.00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
502 Kwo PY, Tector AJ. Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis. Liver Transpl 2013;19:780-1. [PMID: 23775895 DOI: 10.1002/lt.23662] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
503 Kimball P, Stravitz T. DR Antigens Influence Graft Outcome and HCV Recurrence After Liver Transplantation. Transplantation Proceedings 2005;37:1099-100. [DOI: 10.1016/j.transproceed.2004.12.169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
504 Pleguezuelo M, Germani G, Burroughs AK. Liver Transplantation: Prevention and Treatment of Rejection. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 685-723. [DOI: 10.1002/9781444314403.ch42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
505 Colmenero J, Navasa M. Delta-MELD and survival after liver transplantation: the slope matters. Liver Int 2016;36:949-51. [PMID: 26970536 DOI: 10.1111/liv.13112] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
506 Holmes JA, Sievert W, Thompson AJ. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Biomark Med 2011;5:461-78. [PMID: 21861668 DOI: 10.2217/bmm.11.47] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
507 Bárcena R, Gil-Grande L, Moreno J, Foruny JR, Otón E, García M, Blázquez J, Sánchez J, Moreno A, Moreno A. Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. Transplantation 2005;79:1634-5. [PMID: 15940057 DOI: 10.1097/01.tp.0000155424.52939.3d] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
508 Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012;18:1464-1470. [PMID: 22941516 DOI: 10.1002/lt.23542] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
509 Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11(38): 5944-5950 [PMID: 16273604 DOI: 10.3748/wjg.v11.i38.5944] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
510 Moreno R, Berenguer M. Hepatitis C and liver transplantation. Annals of Hepatology 2002;1:129-35. [DOI: 10.1016/s1665-2681(19)32171-4] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
511 Mukherjee S, Gilroy R, Mccashland T, Schafer D. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplantation Proceedings 2003;35:1478-9. [DOI: 10.1016/s0041-1345(03)00446-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
512 Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology. 2009;50:400-406. [PMID: 19472315 DOI: 10.1002/hep.23007] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
513 Karnik GS, Shetty K. Management of recurrent hepatitis C in orthotopic liver transplant recipients. Infect Dis Clin North Am. 2013;27:285-304. [PMID: 23714341 DOI: 10.1016/j.idc.2013.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
514 Pinto Dos Santos D, Kloeckner R, Koch S, Hoppe-Lotichius M, Zöller D, Toenges G, Kremer WM, Zimmermann T, Mittler J, Lang H, Düber C, Galle PR, Weinmann A, Sprinzl MF. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2020;32:626-34. [PMID: 31725030 DOI: 10.1097/MEG.0000000000001552] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
515 Nagai S, Collins K, Chau LC, Safwan M, Rizzari M, Yoshida A, Abouljoud MS, Moonka D. Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies. Clinical Gastroenterology and Hepatology 2019;17:2759-2768.e5. [DOI: 10.1016/j.cgh.2019.04.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
516 Saxena V, Terrault N. Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients. Clin Liver Dis 2015;19:669-88, vi. [PMID: 26466655 DOI: 10.1016/j.cld.2015.06.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
517 Tripon S, Francoz C, Albuquerque A, Paradis V, Boudjema H, Voitot H, Belghiti J, Valla D, Durand F. Interactions between virus-related factors and post-transplant ascites in patients with hepatitis C and no cirrhosis: role of cryoglobulinemia. Transpl Int 2015;28:162-9. [PMID: 25267442 DOI: 10.1111/tri.12466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
518 Polachi N, Bai G, Li T, Chu Y, Wang X, Li S, Gu N, Wu J, Li W, Zhang Y, Zhou S, Sun H, Liu C. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer – A comprehensive review. European Journal of Medicinal Chemistry 2016;123:577-95. [DOI: 10.1016/j.ejmech.2016.07.070] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
519 Camacho JC, Coursey-Moreno C, Telleria JC, Aguirre DA, Torres WE, Mittal PK. Nonvascular post-liver transplantation complications: from US screening to cross-sectional and interventional imaging. Radiographics 2015;35:87-104. [PMID: 25590390 DOI: 10.1148/rg.351130023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
520 Testino G, Leone S, Sumberaz A, Borro P. Liver transplantation in alcoholic patients. Alcohol Clin Exp Res. 2014;38:1800-1802. [PMID: 24033401 DOI: 10.1111/acer.12242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
521 Zarski J, Hilleret M. Treatment of patients with decompensated post-hepatitis C cirrhosis before liver transplantation: strategy to prevent hepatitis C virus (HCV) recurrence? Journal of Hepatology 2003;39:435-6. [DOI: 10.1016/s0168-8278(03)00285-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
522 Forman LM. To transplant or not to transplant recurrent hepatitis C and liver failure. Clinics in Liver Disease 2003;7:615-29. [DOI: 10.1016/s1089-3261(03)00053-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
523 Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, Serrano T, Baliellas C, Figueras J, Garcia-Gil A, Rafecas A; THOSIN Study Group. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008;14:1752-60. [PMID: 19025919 DOI: 10.1002/lt.21629] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
524 Prieto M, Clemente G, Casafont F, Cuende N, Cuervas-mons V, Figueras J, Grande L, Herrero J, Jara P, Mas A, de la Matak M, Navasa M. Documento de consenso de indicaciones de trasplante hepático. Gastroenterología y Hepatología 2003;26:355-75. [DOI: 10.1016/s0210-5705(03)70373-2] [Cited by in Crossref: 15] [Article Influence: 0.8] [Reference Citation Analysis]
525 Navasa M, Forns X. How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation? Liver Transpl 2008;14:1237-9. [DOI: 10.1002/lt.21526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
526 Boyanova Y, Pissaia A, Conti F, Soubrane O, Calmus Y. [Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment]. Presse Med 2006;35:233-6. [PMID: 16493352 DOI: 10.1016/s0755-4982(06)74559-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
527 Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159-1165. [PMID: 14586876 DOI: 10.1053/jlts.2003.50233] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
528 Ackefors M, Gjertsen H, Wernerson A, Weiland O. Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation: Concentration-guided ribavirin dosing with darbepoetin support. Journal of Viral Hepatitis 2012;19:635-9. [DOI: 10.1111/j.1365-2893.2012.01587.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
529 Saab S, Rheem J, Jimenez MA, Fong TM, Mai MH, Kachadoorian CA, Esmailzadeh NL, Bau SN, Kang S, Ramirez SD, Grotts J, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol 2017;5:101-8. [PMID: 28660147 DOI: 10.14218/JCTH.2016.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
530 Arias ABV, Villegas Herrera MT, Arco Sánchez A, Adel ME, Triguero Cabrera J, Plata Illescas C, Montes Osuna MC, Santoyo Villalba J, Villar Del Moral JM. Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C. Transplant Proc 2021:S0041-1345(21)00798-3. [PMID: 34911619 DOI: 10.1016/j.transproceed.2021.08.058] [Reference Citation Analysis]
531 Sher L, Jennings L, Rudich S, Alexopoulos SP, Netto G, Teperman L, Kinkhabwala M, Brown RS, Pomfret E, Klintmalm G; HCV-3 Study Group. Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience: Results of live donor liver transplant for HCV. Clin Transplant 2012;26:502-9. [DOI: 10.1111/j.1399-0012.2011.01561.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
532 Zhang JY, Li YY, Zhang Z, Wang FS. The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes? Hepatol Int 2013;7:948-50. [PMID: 26202024 DOI: 10.1007/s12072-013-9474-8] [Reference Citation Analysis]
533 Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, Charco R, Zieniewicz K, De Carlis L, Duvoux C;  all the contributing centers (www. eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810-817. [PMID: 29940268 DOI: 10.1016/j.jhep.2018.06.010] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 28.0] [Reference Citation Analysis]
534 Yang BS, Liu LX, Yuan M, Hou YB, Li QT, Zhou S, Shi YX, Gao BL. Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations. Diagn Interv Radiol 2020;26:131-9. [PMID: 32071022 DOI: 10.5152/dir.2019.18540] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
535 Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388-398. [PMID: 21168455 DOI: 10.1016/j.jhep.2010.10.044] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
536 Stangl JR, Carroll KL, Illichmann M, Striker R. EFFECT OF ANTIMETABOLITE IMMUNOSUPPRESSANTS ON FLAVIVIRIDAE, INCLUDING HEPATITIS C VIRUS: . Transplantation 2004;77:562-7. [DOI: 10.1097/01.tp.0000114610.40412.c6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
537 Roche B, Samuel D. Liver transplantation in viral hepatitis: Prevention of recurrence. Best Practice & Research Clinical Gastroenterology 2008;22:1153-69. [DOI: 10.1016/j.bpg.2008.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
538 Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, Bignulin S, Cmet S, Fontanini E, Falleti E. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011;24:43-50. [PMID: 20649944 DOI: 10.1111/j.1432-2277.2010.01141.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 9.3] [Reference Citation Analysis]
539 Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387-392. [PMID: 19591128 DOI: 10.1002/hep.23000] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
540 Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int. 2013;26:527-534. [PMID: 23517333 DOI: 10.1111/tri.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
541 Gjertsen H, Weiland O, Oksanen A, Söderdahl G, Broomé U, Ericzon B. Liver Transplantation for HCV Cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplantation Proceedings 2006;38:2675-6. [DOI: 10.1016/j.transproceed.2006.07.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
542 Inoue K, Watanabe T, Yamada M, Yoshikumi H, Ogawa O, Yoshiba M. Efficacy of interferon Beta combined with cyclosporine induction and intensified therapy for retreatment of chronic hepatitis C. Transplant Proc. 2009;41:246-249. [PMID: 19249526 DOI: 10.1016/j.transproceed.2008.10.056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
543 Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 2006;101:1370-1378. [PMID: 16771963 DOI: 10.1111/j.1572-0241.2006.00586.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
544 Méndez-sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-ferraz ML, Soza A, Mendes-correa MC, Chávez-tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-avila JF, Contreras F, Moraes-coelho HS, Parise ER, Bessone F, Uribe M. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology 2014;13:S4-S66. [DOI: 10.1016/s1665-2681(19)30920-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology. 2011;81 Suppl 1:111-115. [PMID: 22212944 DOI: 10.1159/000333270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
546 Boillot O, Dumortier J. Immunosuppression in HCV-positive liver transplant recipients: Pandora's box? Liver Transpl 2007;13:1500-2. [PMID: 17969204 DOI: 10.1002/lt.21224] [Reference Citation Analysis]
547 Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States: Living Donor Liver Transplant and Hepatitis C. Liver Transpl 2004;10:340-6. [DOI: 10.1002/lt.20090] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
548 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
549 Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, Juan FS, López-Labrador FX, Moreno R, Mir J, Berenguer J. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl. 2003;9:228-235. [PMID: 12619018 DOI: 10.1053/jlts.2003.50029] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 4.7] [Reference Citation Analysis]
550 Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl. 2004;10:859-867. [PMID: 15237369 DOI: 10.1002/lt.20157] [Cited by in Crossref: 88] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
551 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
552 Carmiel-Haggai M, Fiel MI, Gaddipati HC, Abittan C, Hossain S, Roayaie S, Schwartz ME, Gondolesi G, Emre S, Schiano TD. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl. 2005;11:1567-1573. [PMID: 16315297 DOI: 10.1002/lt.20517] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
553 Dudley T, Chaplin D, Clifford C, Mutimer DJ. Quality of life after liver transplantation for hepatitis C infection. Qual Life Res 2007;16:1299-308. [DOI: 10.1007/s11136-007-9244-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
554 Lens S, Mariño Z, Forns X. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Dig Liver Dis 2014;46 Suppl 5:S197-205. [PMID: 25458782 DOI: 10.1016/j.dld.2014.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
555 Baltz AC, Trotter JF. Living donor liver transplantation and hepatitis C. Clinics in Liver Disease 2003;7:651-65. [DOI: 10.1016/s1089-3261(03)00058-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
556 Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013;19:690-700. [PMID: 23696372 DOI: 10.1002/lt.23669] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 10.1] [Reference Citation Analysis]
557 Llado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol. 2005;42:468-472. [PMID: 15763328 DOI: 10.1016/j.jhep.2005.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
558 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1191/0961203305lu2122oa] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
559 Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl. 2013;19:36-48. [PMID: 22821730 DOI: 10.1002/lt.23516] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
560 Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-548. [PMID: 23199510 DOI: 10.1016/j.bpg.2012.09.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
561 Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol 2015;42:1030-5. [DOI: 10.1111/1440-1681.12451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
562 Thompson N, Hellinger W, Kay R, Cohen L, Ragan P, Voss R, Bacalis L, Xia G, Keating M, Dickson R, Hughes C, Williams I, Perz J. Healthcare-associated hepatitis C virus transmission among patients in an abdominal organ transplant center. Transplant Infectious Disease 2009;11:324-9. [DOI: 10.1111/j.1399-3062.2009.00406.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
563 Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, D'Alteroche L, Leroy V, Canva V, Lebray P, Moreno C, Dumortier J, Silvain C, Besch C, Perre P, Botta-Fridlund D, Anty R, Francoz C, Abergel A, Debette-Gratien M, Conti F, Habersetzer F, Rohel A, Rossignol E, Danjou H, Roque-Afonso AM, Samuel D, Duclos-Vallée JC, Pageaux GP; ANRS C023 CUPILT study group. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. J Hepatol 2016;65:711-8. [PMID: 27262758 DOI: 10.1016/j.jhep.2016.05.039] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 10.7] [Reference Citation Analysis]
564 Castro-Narro GE. [Liver transplantation]. Rev Gastroenterol Mex 2012;77 Suppl 1:94-6. [PMID: 22939497 DOI: 10.1016/j.rgmx.2012.07.036] [Reference Citation Analysis]
565 Manousou P, Dhillon AP, Isgro G, Calvaruso V, Luong TV, Tsochatzis E, Xirouchakis E, Kalambokis G, Cross TJ, Rolando N, O'Beirne J, Patch D, Thornburn D, Burroughs AK. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl. 2011;17:178-188. [PMID: 21280191 DOI: 10.1002/lt.22209] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
566 Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, Adeyi O, McGilvray I, Cattral M, Greig PD. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl. 2008;14:1778-1786. [PMID: 19025914 DOI: 10.1002/lt.21598] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
567 Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459-465. [PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017] [Cited by in Crossref: 159] [Cited by in F6Publishing: 139] [Article Influence: 9.9] [Reference Citation Analysis]
568 Martin EF, Huang J, Xiang Q, Klein JP, Bajaj J, Saeian K. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl. 2012;18:914-929. [PMID: 22467623 DOI: 10.1002/lt.23440] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
569 Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15:1343-1350. [PMID: 19790164 DOI: 10.1002/lt.21788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
570 Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, Colombo M. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int. 2015;35:1-4. [PMID: 25074044 DOI: 10.1111/liv.12646] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
571 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
572 Toussaint-Miller KA, Andres J. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Ann Pharmacother 2015;49:1015-30. [PMID: 26139639 DOI: 10.1177/1060028015592015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
573 Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, Radenne S, d'Alteroche L, Fougerou-Leurent C, Canva V, di Martino V, Conti F, Kamar N, Moreno C, Lebray P, Tran A, Besch C, Diallo A, Rohel A, Rossignol E, Abergel A, Botta-Fridlund D, Coilly A, Samuel D, Duclos-Vallée JC, Pageaux GP. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver Transpl 2016;22:1367-78. [PMID: 27348086 DOI: 10.1002/lt.24505] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
574 Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl. 2011;17:289-298. [PMID: 21384511 DOI: 10.1002/lt.22235] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
575 Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, Allende H, Charco R, Esteban R. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients. Transplantation 2012;93:450-3. [PMID: 22262129 DOI: 10.1097/TP.0b013e318240e9dd] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
576 Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-judaibi B, Renner EL, Lilly LB. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Annals of Hepatology 2014;13:525-32. [DOI: 10.1016/s1665-2681(19)31252-9] [Cited by in Crossref: 21] [Article Influence: 2.6] [Reference Citation Analysis]
577 Gaglio PJ, Malireddy S, Levitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, Russo MW, Emond JC, Brown RS. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl. 2003;9:1028-1035. [PMID: 14526396 DOI: 10.1053/jlts.2003.50211] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 5.8] [Reference Citation Analysis]
578 Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 2018;69:603-7. [PMID: 29886154 DOI: 10.1016/j.jhep.2018.05.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
579 Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. Transpl Int. 2012;25:448-454. [PMID: 22353419 DOI: 10.1111/j.1432-2277.2012.01440.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
580 Joshi D, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther. 2013;37:659-671. [PMID: 23432320 DOI: 10.1111/apt.12260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
581 Burton JR, Rosen HR. Treatment of HCV recurrence: Do the pretransplantation rules apply? Liver Transpl 2006;12:1044-8. [DOI: 10.1002/lt.20783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
582 Kishi Y, Sugawara Y, Kaneko J, Tamura S, Matsui Y, Makuuchi M. Blood eosinophilia after living donor liver transplantation for hepatitis C virus-related cirrhosis. Transplant Proc 2007;39:1540-3. [PMID: 17580184 DOI: 10.1016/j.transproceed.2006.12.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
583 Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol 2007;41:66-74. [PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
584 Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017;11:2131-8. [PMID: 28744104 DOI: 10.2147/DDDT.S139837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
585 Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, Maimone S, Pleguezuelo M, Xirouchakis I, Guerrini GP. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology. 2009;49:1236-1244. [PMID: 19133646 DOI: 10.1002/hep.22745] [Cited by in Crossref: 184] [Cited by in F6Publishing: 164] [Article Influence: 14.2] [Reference Citation Analysis]
586 Rendina M, D'Amato M, Castellaneta A, Castellaneta NM, Brambilla N, Giacovelli G, Rovati L, Rizzi SF, Zappimbulso M, Bringiotti RS, Di Leo A. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Transpl Int 2014;27:696-704. [PMID: 24673819 DOI: 10.1111/tri.12324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
587 Elsabbagh AM, Girlanda R, Hawksworth J, Pichert MD, Williams C, Pozzi A, Kroemer A, Nookala A, Smith C, Matsumoto CS, Fishbein TM. Impact of early reoperation on graft survival after liver transplantation: Univariate and multivariate analysis. Clin Transplant 2018;32:e13228. [PMID: 29478256 DOI: 10.1111/ctr.13228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
588 Zignego AL, Giannini C, Gragnani L, Piluso A, Fognani E. Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med. 2012;10:158. [PMID: 22863056 DOI: 10.1186/1479-5876-10-158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
589 Lawal A, Ghobrial R, Te H, Artinian L, Eastwood D, Schiano TD. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation. Transplant Proc. 2007;39:3261-3265. [PMID: 18089367 DOI: 10.1016/j.transproceed.2007.08.106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
590 Nudo CG, Yoshida EM, Bain VG, Marleau D, Wong P, Marotta PJ, Renner E, Watt KD, Deschênes M. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol 2008;22:821-4. [PMID: 18925305 DOI: 10.1155/2008/418485] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
591 Zhang L, Lu Q, Yang Z, Wang X, Cai L, Liu X, Liao R, Yang X, Chen Y, Yang Z. Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis. Hum Immunol 2014;75:1268-75. [PMID: 25225180 DOI: 10.1016/j.humimm.2014.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
592 Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752-1762. [PMID: 22821361 DOI: 10.1002/hep.25976] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 10.1] [Reference Citation Analysis]
593 Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011;11:1676-1685. [PMID: 21564522 DOI: 10.1111/j.1600-6143.2011.03508.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
594 Kim RD, Mizuno S, Sorensen JB, Schwartz JJ, Fujita S. Impact of Calcineurin Inhibitors on Hepatitis C Recurrence After Liver Transplantation. Dig Dis Sci 2012;57:568-72. [DOI: 10.1007/s10620-011-1871-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
595 Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P; ITACOPS study group. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int 2017;30:1253-65. [PMID: 28799277 DOI: 10.1111/tri.13018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
596 Asaoka T, Kato T, Marubashi S, Dono K, Hama N, Takahashi H, Kobayashi S, Takeda Y, Takemasa I, Nagano H. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl. 2009;15:1738-1749. [PMID: 19938108 DOI: 10.1002/lt.21883] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
597 Kawaoka T, Takahashi S, Kawakami Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Aikata H, Ishiyama K, Tashiro H, Ohdan H, Tanaka J, Chayama K. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation: SVR in outcome of antiviral therapy post-LT HCV. Hepatol Res 2015;45:1047-54. [DOI: 10.1111/hepr.12447] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
598 Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation. 2006;81:620-622. [PMID: 16495812 DOI: 10.1097/01.tp.0000181192.13836.8c] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
599 Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma 2014;1:109-14. [PMID: 27508180 DOI: 10.2147/JHC.S60867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
600 Kemmer NM, Neff GW. Liver Transplantation Trends and Survival in the Asian Population. Transplantation 2009;88:392-4. [DOI: 10.1097/tp.0b013e3181aed68c] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
601 Campos-Varela I, Esteban JI, Bes M, Caralt M, Allende H, Rodríguez-Frías F, Salcedo MT, Sauleda S, Charco R, Guardia J, Esteban R, Castells L. Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1. J Viral Hepat 2014;21:e118-28. [PMID: 24620835 DOI: 10.1111/jvh.12246] [Reference Citation Analysis]
602 Baiocchi L, Angelico M, Petrolati A, Perrone L, Palmieri G, Battista S, Carbone M, Tariciotti L, Longhi C, Orlando G. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant. 2008;8:673-678. [PMID: 18294164 DOI: 10.1111/j.1600-6143.2007.02107.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
603 Kwo PY, Saxena R, Cummings OW, Tector AJ. Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. Liver Transpl 2007;13:1710-3. [DOI: 10.1002/lt.21295] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
604 Li DL, Liu BR. A review of differences in cirrhosis between men and women and characteristics of cirrhosis in females. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1763-1769 [DOI: 10.11569/wcjd.v23.i11.1763] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
605 McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl. 2004;10:975-985. [PMID: 15390322 DOI: 10.1002/lt.20213] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
606 Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118-124. [PMID: 15636619 DOI: 10.1111/j.1600-6143.2004.00648.x] [Cited by in Crossref: 156] [Cited by in F6Publishing: 125] [Article Influence: 9.2] [Reference Citation Analysis]
607 Lucey MR. Liver transplantation for alcoholic liver disease. Clin Liver Dis. 2007;11:283-289. [PMID: 17606207 DOI: 10.1016/j.cld.2007.04.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
608 Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. Transplant Proc 2017;49:1634-8. [PMID: 28838454 DOI: 10.1016/j.transproceed.2017.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
609 Carbone M, Lenci I, Baiocchi L. Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther 2012; 3(4): 36-48 [PMID: 22966482 DOI: 10.4292/wjgpt.v3.i4.36] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
610 Park JI, Choi KM, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Chung YH, Lee YS, Suh DJ. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis]. Korean J Hepatol 2007;13:543-55. [PMID: 18159152 DOI: 10.3350/kjhep.2007.13.4.543] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
611 Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011;17:1394-1403. [PMID: 21850690 DOI: 10.1002/lt.22417] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
612 Kimball P, Verbeke S, Shiffman M. HCV Core Protein Augments Cyclosporine Immunosuppression. Transplantation Proceedings 2005;37:652-3. [DOI: 10.1016/j.transproceed.2004.12.293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
613 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
614 Colombo M, Sangiovanni A. How I manage my patients with hepatocellular carcinoma. Liver Int 2011;31 Suppl 1:145-50. [PMID: 21205153 DOI: 10.1111/j.1478-3231.2010.02381.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
615 Ueda Y, Takada Y, Haga H, Nabeshima M, Marusawa H, Ito T, Egawa H, Tanaka K, Uemoto S, Chiba T. Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation. Transplantation 2008;85:855-62. [DOI: 10.1097/tp.0b013e3181671df0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
616 Lai PC, Chen CH, Jeng LB, Yu TM, Tsai SF, Wu MJ, Cheng SB, Yang SS, Lee TY. Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection. Antimicrob Agents Chemother 2021;:AAC0200321. [PMID: 34902265 DOI: 10.1128/AAC.02003-21] [Reference Citation Analysis]
617 Wright TL. How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration? Liver Transplantation;9:S109-13. [DOI: 10.1053/jlts.2003.50259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
618 Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148:13-16. [PMID: 25451651 DOI: 10.1053/j.gastro.2014.11.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
619 Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayón M, San Juan F, Landaverde C, Mir J, Berenguer J. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl. 2003;9:1152-1158. [PMID: 14586875 DOI: 10.1053/jlts.2003.50240] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
620 Pyrsopoulos N, Jeffers L. Hepatitis C in African Americans. J Clin Gastroenterol 2007;41:185-93. [PMID: 17245218 DOI: 10.1097/01.mcg.0000225689.60335.44] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
621 Oton E, Barcena R, Garcia-Garzon S, Moreno-Zamora A, Moreno A, Garcia-Gonzalez M, Blesa C, Foruny JR, Ruiz P. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc. 2005;37:3963-3964. [PMID: 16386597 DOI: 10.1016/j.transproceed.2005.10.060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
622 Herzer K, Gerken G. When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation. Visc Med 2016;32:258-62. [PMID: 27722162 DOI: 10.1159/000446976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
623 Bizollon T, Trepo C. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months? Journal of Hepatology 2002;37:274-6. [DOI: 10.1016/s0168-8278(02)00200-3] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
624 Toniutto P, Fabris C, Bitetto D, Falleti E, Avellini C, Rossi E, Smirne C, Minisini R, Pirisi M. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol. 2007;22:1904-1908. [PMID: 17914968 DOI: 10.1111/j.1440-1746.2006.04628.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
625 Fortune BE, Trotter JF. Posttransplantation treatment of recurrent hepatitis C: is the juice worth the squeeze? Am J Transplant 2008;8:2183-4. [PMID: 18925900 DOI: 10.1111/j.1600-6143.2008.02439.x] [Reference Citation Analysis]
626 McCashland TM. Management of liver transplant recipients with recurrent hepatitis C. Curr Opin Organ Transplant 2009;14:221-4. [PMID: 19444107 DOI: 10.1097/MOT.0b013e32832ade76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
627 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
628 Coilly A, Roche B, Duclos-vallée JC, Samuel D. News and challenges in the treatment of hepatitis C in liver transplantation. Liver Int 2016;36:34-42. [DOI: 10.1111/liv.13017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
629 Lan BY, Landry GM, Tan VO, Bostrom A, Feng S. Ascites in Hepatitis C Liver Transplant Recipients Frequently Occurs in the Absence of Advanced Fibrosis: Ascites in Hepatitis C Liver Transplant Recipients. American Journal of Transplantation 2008;8:366-76. [DOI: 10.1111/j.1600-6143.2007.02046.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
630 Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, Sundaram V, Charlton M. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl 2019;25:598-609. [PMID: 30716208 DOI: 10.1002/lt.25424] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
631 Fu H, Dong J, Sun Z, Zhang X, Yu A, Chen G, Li W. Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis. Ann Transl Med 2020;8:648. [PMID: 32566585 DOI: 10.21037/atm-20-3074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
632 Venturi C, Bueno J, Castells L, Quintero J, Casas I, Allende H, Martinez-Ibañez V, Charco R. Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation. Liver Transpl 2011;17:1474-80. [PMID: 21932378 DOI: 10.1002/lt.22439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
633 Bunchorntavakul C, Reddy KR. Donation after cardiac death organs for patients with hepatitis C virus: are we rolling the dice, or are they just as good as any? Liver Transpl 2011;17:625-7. [PMID: 21491581 DOI: 10.1002/lt.22313] [Reference Citation Analysis]
634 Barrault C, Roudot-Thoraval F, Tran Van Nhieu J, Atanasiu C, Kluger MD, Medkour F, Douvin C, Mallat A, Zafrani ES, Cherqui D, Duvoux C. Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation. Clin Res Hepatol Gastroenterol. 2013;37:347-352. [PMID: 23318116 DOI: 10.1016/j.clinre.2012.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
635 Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation 2017;101:1001-8. [PMID: 27926593 DOI: 10.1097/TP.0000000000001605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
636 Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34. [PMID: 14586892 DOI: 10.1053/jlts.2003.50248] [Cited by in Crossref: 170] [Cited by in F6Publishing: 153] [Article Influence: 9.4] [Reference Citation Analysis]
637 Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011;17:528-538. [PMID: 21506241 DOI: 10.1002/lt.22271] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
638 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
639 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1177/096120330501400114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
640 Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 2006;12:762-767. [PMID: 16528713 DOI: 10.1002/lt.20655] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
641 Khan R, Singal AK, Anand BS. Outcomes after liver transplantation for combined alcohol and hepatitis C virus infection. World J Gastroenterol 2014; 20(34): 11935-11938 [PMID: 25232228 DOI: 10.3748/wjg.v20.i34.11935] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
642 Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137:1986-94. [PMID: 19747918 DOI: 10.1053/j.gastro.2009.08.067] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
643 Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Fukuhara T, Kotoh K, Shimoda S, Kato M, Maehara Y. The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C. Transplantation Proceedings 2009;41:4246-52. [DOI: 10.1016/j.transproceed.2009.08.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
644 Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transplantation;9:S79-89. [DOI: 10.1053/jlts.2003.50257] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
645 Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci 2013;58:3010-6. [PMID: 23812862 DOI: 10.1007/s10620-013-2749-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
646 Hirose K, Stock PG. Liver transplantation in the human immunodeficiency virus-positive patient: . Current Opinion in Organ Transplantation 2006;11:241-6. [DOI: 10.1097/01.mot.0000227839.83710.e5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
647 Brandl A, Stolzlechner P, Eschertzhuber S, Aigner F, Weiss S, Vogel W, Krannich A, Neururer S, Pratschke J, Graziadei I. Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients-5-year single-center experience. Transpl Int. 2016;29:471-482. [PMID: 26716608 DOI: 10.1111/tri.12741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
648 Howell J, Sawhney R, Skinner N, Gow P, Angus P, Ratnam D, Visvanathan K. Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression post-liver transplantation. Am J Transplant. 2013;13:943-953. [PMID: 23425350 DOI: 10.1111/ajt.12165] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
649 Xu M, Brown RS. Liver Transplantation for the Referring Physician. Clinics in Liver Disease 2015;19:135-53. [DOI: 10.1016/j.cld.2014.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
650 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
651 Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Transplant Proc. 2011;43:3824-3828. [PMID: 22172854 DOI: 10.1016/j.transproceed.2011.08.103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
652 Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15:1063-1071. [PMID: 19718647 DOI: 10.1002/lt.21784] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
653 Verna EC, Brown RS. Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted. Clinics in Liver Disease 2008;12:637-59. [DOI: 10.1016/j.cld.2008.03.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
654 Encke J, Kraus T, Mehrabi A, Stremmel W, Sauer P. Treatment of Hepatitis C Virus Reinfection after Liver Transplantation. Transplantation 2005;80:S125-7. [DOI: 10.1097/01.tp.0000186906.47521.d7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
655 Melum E, Schrumpf E, Bjøro K. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation. Scand J Gastroenterol 2006;41:592-6. [PMID: 16638703 DOI: 10.1080/00365520500347113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
656 Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Fernández I, Martín-Arriscado C, Caso Ó. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study. Int J Surg 2021;91:105981. [PMID: 34098075 DOI: 10.1016/j.ijsu.2021.105981] [Reference Citation Analysis]
657 Berenguer M, Prieto M, Palau A, Carrasco D, Rayón JM, Calvo F, Berenguer J. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol. 2004;16:1207-1212. [PMID: 15489583 DOI: 10.1097/00042737-200411000-00020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
658 Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Caldato M, Rossi E, Bitetto D, Minisini R, Smirne C, Pirisi M. Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. J Interferon Cytokine Res 2007;27:239-46. [PMID: 17348823 DOI: 10.1089/jir.2006.0062] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
659 Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Yamashiki N, Kokudo N. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One 2014;9:e90462. [PMID: 24599320 DOI: 10.1371/journal.pone.0090462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
660 Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012;18:1029-1036. [PMID: 22641474 DOI: 10.1002/lt.23479] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
661 Saleh MI. A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients. Clin Pharmacokinet 2017;56:1369-79. [DOI: 10.1007/s40262-017-0527-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
662 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
663 Pillai A, Lee V, Wang E, Rinella M, Levitsky J. Factors Associated With Sustained Virological Response in Liver Transplant Recipients With Recurrent Hepatitis C. Transplantation Proceedings 2010;42:3647-51. [DOI: 10.1016/j.transproceed.2010.06.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
664 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
665 Dall’Agata M, Gramenzi A, Biselli M, Bernardi M. Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents? World J Gastroenterol 2014; 20(28): 9253-9260 [PMID: 25071318 DOI: 10.3748/wjg.v20.i28.9253] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
666 Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl. 2004;10:1263-1268. [PMID: 15376301 DOI: 10.1002/lt.20254] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
667 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 2009;9:S116-30. [DOI: 10.1111/j.1600-6143.2009.02902.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
668 Girometti R, Como G, Bazzocchi M, Zuiani C. Post-operative imaging in liver transplantation: State-of-the-art and future perspectives. World J Gastroenterol 2014; 20(20): 6180-6200 [PMID: 24876739 DOI: 10.3748/wjg.v20.i20.6180] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
669 Porter SB, Reddy KR. Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. Clin Liver Dis. 2003;7:603-614. [PMID: 14509529 DOI: 10.1016/s1089-3261(03)00055-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
670 Kaibori M, Ha-Kawa SK, Kamiyama Y. Usefulness of TC-99M GSA liver scintigraphy for the assessment of recurrent hepatitis C after living-donor liver transplantation: a case report. Transplant Proc 2008;40:2837-9. [PMID: 18929877 DOI: 10.1016/j.transproceed.2008.07.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
671 Ferrarese A, Zanetto A, Gambato M, Bortoluzzi I, Nadal E, Germani G, Senzolo M, Burra P, Russo FP. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 2016; 22(4): 1570-1581 [PMID: 26819523 DOI: 10.3748/wjg.v22.i4.1570] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
672 Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI. Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 2006;43:973-81. [PMID: 16628627 DOI: 10.1002/hep.21157] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
673 Chen Y, Wu G, Zhang H, Xu H, Li H, Chen L, Yang Y, Hu P, Zhang D, Ren H, Hu H. Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract 2015;2015:206302. [PMID: 26167174 DOI: 10.1155/2015/206302] [Reference Citation Analysis]
674 Mueller JL, King LY, Johnson KB, Gao T, Nephew LD, Kothari D, Simpson MA, Zheng H, Wei L, Corey KE, Misdraji J, Lee JH, Lin MV, Gogela NA, Fuchs BC, Tanabe KK, Gordon FD, Curry MP, Chung RT. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant 2016;30:452-60. [PMID: 26854475 DOI: 10.1111/ctr.12710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
675 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by